elcc 2015 final programme - · pdf filelast update: 09-03-2015 04:51:41pm elcc 2015 14:30 -...

Last update: 09-03-2015 04:51:41pm ELCC 2015

04-15-2015

13:15 - 13:40 Welcome Reception Hall 1

13:45 - 14:00 Opening and Welcome Room B

Chair: D. Grunenwald, FR; J. Vansteenkiste, BE

13:45 - 13:50 Welcome to the Conference

, ; FR, BED. Grunenwald1 J. Vansteenkiste2 1 2

13:50 - 13:55 Introduction by the ESMO President

, CHR. Stahel

13:55 - 14:00 Introduction by the IASLC President

, CNT. Mok

14:00 - 14:30 The development of oncological platforms across Europe Room B


14:00 - 14:30 The development of oncological platforms across Europe

, CHR. Stahel

14:30 - 16:00 Local control after treatment of early stage lung cancer Room B

Chair: D. Zips, DE; D. Jones, US

14:30 - 14:50 Stereotactic ablative RT after surgical treatment

, NLS. Senan

14:50 - 15:10 Surgery after stereotactic ablative RT

, BEP. Van Schil

15:10 - 15:30 Surgery after radiofrequency ablation

, DEH. Dienemann

15:30 - 15:50 Surgery for metachronous lung tumours

, USD. Jones

15:50 - 16:00 Questions and Answers

http://www.esmo.org/Conferences/ELCC-2015-Lung-Cancer?hit=Prog


14:30 - 16:00 The evolving role of immunotherapy for lung cancer Room A

Chair: A.-M. Dingemans, NL; M. Reck, DE

14:30 - 14:50 Checkpoint inhibitors: State of the art

, CHS. Peters

14:50 - 15:10 Combination strategies

, DEM. Reck

15:10 - 15:30 Is there any room left for vaccines in lung cancer?

, BEJ. Vansteenkiste

15:30 - 15:50 Clinical trial design and perspectives

, OH/USD. Carbone


16:30 - 18:00 Mesothelioma: The rare disease that we need to know better Room B

Chair: P. Baas, NL; W. Weder, CH

16:30 - 16:50 Sequencing the mesothelioma genome in 2015

, ITG. Scagliotti

16:50 - 17:10 The evolving role of the thoracic surgeon

, CHW. Weder

17:10 - 17:30 Radiotherapist: A controversial role in this disease

, ITU. Ricardi

17:30 - 17:50 Systemic treatment: Old drugs or new approaches?

, NLP. Baas




16:30 - 18:00 Toxicity management of targeted agents Room A

Chair: E. Smit, NL

16:30 - 16:50 Management of skin toxicity

, FRV. Sibaud

16:50 - 17:10 Other toxicities of targeted agents and their management

, ITS. Novello

17:10 - 17:30 Interactions between targeted agents and concomitant meds including life style

, NLR. Mathijssen

17:30 - 17:50 Interaction between radiotherapy and targeted agents: Toxicity issues


04-16-2015

08:00 - 08:50 Oncogene-driven early stage NSCLC Room A

Chair: Y.-L. Wu, CN; M. Kris, US

08:00 - 08:15 Should we test for EGFR and ALK in completely resected NSCLC?

, CNY.-L. Wu

08:15 - 08:30 How should completely resected stage II-III with activating EGFR mutation be treated? ongoingstudies

, NY/USM. Kris

08:30 - 08:50 Discussion

08:00 - 08:50 How do we provide the best psychological care for patients with thoracic malignancies? Room V

Chair: J.-L. Pujol, FR; T. Berghmans, BE

08:00 - 08:15 The holistic approach of the patient

, FRJ.-L. Pujol

08:15 - 08:30 The provision of early palliative care

, BET. Berghmans




08:00 - 08:50 Molecularly-driven targeted agents for advanced NSCLC Room X

Chair: R. Califano, UK; M. Petrova, BG

08:00 - 08:20 Overcoming resistance to first-/second-generation EGFR-TKIs and ALK-inhibitors inoncogene-addicted advanced NSCLC

, UKR. Califano

08:20 - 08:40 Novel therapies for advanced squamous cell carcinoma

, GRG. Mountzios


09:00 - 10:30 Management of neuro-endocrine tumours other than SCLC Room A

Chair: R. Cerfolio, US; C. Gridelli, IT

09:00 - 09:20 Radionuclide techniques for staging and treatment

, FRE. Baudin

09:20 - 09:40 Local therapies

, DEB. Passlick

09:40 - 10:00 Systemic therapy

, ITC. Gridelli

10:00 - 10:20 Review of a current guideline

, ITP. Ferolla


09:15 - 10:15 Is immunotherapy a first-line treatment for NSCLC? Room B

Chair: F. Hirsch, US; J. Vansteenkiste, BE

09:15 - 09:25 Introduction and first vote

09:25 - 09:45 Yes

, FRJ.-C. Soria

09:45 - 10:05 No

, AUK. O'Byrne

10:05 - 10:15 Second vote and conclusions

09:15 - 10:30 Medical and radiation oncology Room V

Chair: C. Manegold, DE; G. Scagliotti, IT; S. Senan, NL



09:15 - 09:15 100PD - A prospective randomized open label phase III study of maintenance gemcitabine versusbest supportive care following platinum-paclitaxel chemotherapy for patients with advancednon-small cell lung cancer

, S. Narayan, A. Kapoor, S. Beniwal, M. Singhal, P. Kumari, G. Singh, S. Kumari, H. Kumar, M.S. JakharBardia; IN

09:15 - 09:15 101PD - A prospective randomized open label phase III study of geftinib versus docetaxel assecond or third line therapy in patients with advanced non small cell lung cancer in Asian Indians

, N. Kumar, S. Narayan, R. Nirban, S. Maharia, S. Beniwal, S. Jakhar, H. Kumar; INA. Kapoor

09:15 - 09:25 Invited Discussant

, DEC. Manegold


09:30 - 09:30 102PD - A randomized, double-blind, phase 2 trial of veliparib (ABT-888) with carboplatin andpaclitaxel in previously untreated metastatic or advanced non-small cell lung cancer

, N. Blais , E. Juhasz , L. Urban , S. Orlov , Q. Qin , M. McKee , V. Giranda , V.J. Mazieres1 2 3 3 4 5 5 5

Gorbunova , S. Ramalingam ; FR, CA, HU, RU, IL/US, GA/US4 6 1 2 3 4 5 6

09:30 - 09:30 103PD - Subgroup analysis of elderly patients in SQUIRE: A randomized, multicenter, open-label,phase III study of necitumumab (N) plus gemcitabine-cisplatin (GC) chemotherapy versus GCalone in first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer(sq-NSCLC)

, T.-E. Ciuleanu , R. Ramlau , C. Schumann , L. Paz-Ares , H. Depenbrock , S. Nanda ,N. Thatcher1 2 3 4 1 4 5

N. Chouaki , M. Socinski ; UK, RO, PL, DE, NJ/US, FR, PA/US6 7 1 2 3 4 5 6 7

09:30 - 09:30 37PD - SNPs in angiogenic factors as predictive markers for outcome in patients (p) withadvanced non-squamous NSCLC (NS-NSCLC) treated with carboplatin, paclitaxel (CP) andbevacizumab (Bev). Final results of ANGIOMET Spanish Lung Cancer Group Trial

, E. Jantus-Lewintre, J. Gonzalez-Larriba, D. Rodriguez Abreu, O. Juan, M. Domine,B. Massuti SuredaM. Provencio Pulla, J. de Castro, C. Camps, R. Rosell; ES

09:30 - 09:30 LBA4 - Evaluation of anaplastic lymphoma kinase (ALK) inhibitor brigatinib [AP26113] in patients(Pts) with ALK+ non–small cell lung cancer (NSCLC) and brain metastases

, S. Gettinger , K. Gold , C. Langer , A. Shaw , L. Bazhenova , R. Salgia , D. Dorer , M.D. Kerstein1 1 2 1 1 3 4 1

Conlan , D..R. Camidge ; US, TX/US, CA/US, IL/US, CO/US1 5 1 2 3 4 5


, ITG. Scagliotti


10:00 - 10:00 38PD - CT characteristics allow the identification of patient-specific and regional susceptibility forradiation-induced lung damage

, W. van Elmpt , W. Crijns , P. Slagmolen , D. De Ruysscher ; BE, NLG. Defraene1 2 1 1 1 1 2

10:00 - 10:00 156PD - Optimization of gross tumour volume definition and treatment planning in lung-sparingvolumetric modulated arc therapy for pleural mesothelioma

, G. Defraene, K. Nackaerts, C. Deroose, J. Coolen, P. Nafteux, S. Peeters, D. DeA. BotticellaRuysscher; BE



10:00 - 10:00 82PD - The volume matters in stage III NSCLC patients treated with concurrentchemoradiotherapy

, C. Chen, W. Heemsbergen, M. van den Heuvel, J. Belderbos, J.-J. Sonke; NLJ. van Diessen

10:00 - 10:00 83PD - Prognosis of stage III non-small-cell lung cancer patients presenting with isolated brainfailure after definitive concurrent chemoradiation therapy

, O. Guler, B. Yildirim; TRE. Topkan


, NLS. Senan


11:00 - 12:30 How do we improve the outcome of stage III NSCLC? Room B

Chair: B. Passlick, DE; W. Eberhardt, DE

11:00 - 11:20 Selection of patients for multimodality treatment decision

, DEW. Eberhardt

11:20 - 11:40 Optimal staging of mediastinal lymph nodes

, DEC. Dooms

11:40 - 12:00 The place of neo-adjuvant or adjuvant radiotherapy

, FRC. Le Pechoux

12:00 - 12:20 Improving stage III outcome: Any perspective?

, BEP. De Leyn

12:20 - 12:30 Questions and Answers / Panel Discussion



11:00 - 12:30 Personalised radiotherapy Room A

Chair: C. West, UK; S. Senan, NL

11:00 - 11:20 The role of genetics in personalised radiotherapy

, UKC. West

11:20 - 11:40 Organs at risk: How to individualise?

, BED. De Ruysscher

11:40 - 12:00 Radiomics for tumours: The future for personalised radiotherapy?

, USO. Gevaert

12:00 - 12:20 How to individualise the combination of radiotherapy with drugs

, DED. Zips


11:00 - 12:30 Contemporary resection techniques for stage I lung cancer Room C

Chair: H. Asamura, JP; W. Weder, CH

11:00 - 11:20 Minimally invasive open and hybrid techniques: Morbidity and long term results

, JPH. Asamura

11:20 - 11:40 Conventional VATS lobectomy/segmentectomy: Morbidity and long term results

, FRJ. Assouad

11:40 - 12:00 Uniportal VATS lobectomy/segmentectomy: Morbidity and long term results

, ESD. Gonzales-Rivas

12:00 - 12:20 Robotic lobectomy/segmentectomy: Morbidity and long term results

, AL/USR. Cerfolio




11:00 - 12:30 The diagnostic challenge of small nodules Room W

Chair: J. Vansteenkiste, BE; G. Veronesi, IT

11:00 - 11:20 Optimal follow-up of incidental nodules

, BEW. De Wever

11:20 - 11:40 Possibilities and limitations of endoscopy

, BEV. Ninane

11:40 - 12:00 Possibilities and limitations of transthoracic procedures

, DES. Diederich

12:00 - 12:20 Can biomarkers be of help in the diagnosis?

, ITG. Veronesi


11:00 - 12:30 Pathology in translation Room X

Chair: A. Warth, DE; E. Thunnissen, NL

11:00 - 11:20 Proliferation in lung cancer: Worth measuring?

, DEA. Warth

11:20 - 11:40 EQA for biomarker testing on the move

, NLE. Thunnissen

11:40 - 12:00 Diagnosing mesothelioma: An ongoing challenge

, PA/USS. Dacic

12:00 - 12:20 Liquid biopsies: CTCs and cell-free DNA for monitoring NSCLC

, USS. Finn


12:30 - 13:10 Poster lunch Hall 1

12:30 - 12:30 TUMOUR BIOLOGY AND PATHOLOGY

12:30 - 12:30 2P - EGFR mutation is not a rare issue for peripheral squamous carcinoma of lung

, L. Zhu, P. Gu, Y. Zhang, B. Han, J. Zhang; CNQ. Zhang

12:30 - 12:30 3P - EGFR mutations in non-small cell lung cancer in South Africa

, C. Maske, P. Ruff; ZAS.W. Chan

12:30 - 12:30 5P - Reliable EGFR mutation testing in ultrasound guided supraclavicular lymph node fine needleaspirates: A cohort study with diagnostic performance analysis



, S. Tiwari, V. Sovani, D. Baldwin, M. Kumaran; UKA. Awwad

12:30 - 12:30 6P - Screening for the prevalence of EGFR and ALK mutations in lung adenocarcinoma patients inthe Levant area, a prospective analysis

, M. Khalil , A. Mina , H. Rafei , N. Fakhreddin , R. Mahfouz , F. Farhat , S. Hamouri , H.A. Tfayli1 2 1 1 1 1 1 3

Dbouk , G. Zaatari ; LB, US, JO1 1 1 2 3

12:30 - 12:30 7P - Frequency of ALK gene rearrangement in Saudi lung cancer

, H. Al Husaini, S. Mohammed, A. Tulbah, K. Al Kuraya; SAF. Al Dayel

12:30 - 12:30 8P - PD1/PD-L1 expression in NSCLC differs according to localisation, grading and subtype

, A. Csanadi, C. Kayser, S. Wiesemann, J. Rawluk, M. Werner, G. Kayser; DEF. Brühl

12:30 - 12:30 9P - Distribution of T cells in non-small cell lung cancer tissue according to COPD and smokingstatus

, M. Zemaitis, D. Pranys, B. Sitkauskiene, S. Miliauskas, R. Sakalauskas; LTJ. Jackute

12:30 - 12:30 10P - Allele frequency of ABO and Rh blood group and the risk of non small cell lung carcinoma

, N. Kumar, A. Kalwar, S. Narayan, R. Nirban, S. Jakhar, S. Beniwal, N. Sharma, H. Kumar, A.A. KapoorSharma; IN

12:30 - 12:30 11P - The comparative estimation of estrogen receptor beta expression in primary and metastaticlung cancer

, E. Dudko, E. Bogush, A. Grishanina, V. Kirsanov, R. Ramanauskaite, B. Polotsky, S.T. BogushTjulandin, M. Davydov; RU

12:30 - 12:30 12P - A molecular case–control investigation of the merkel cell polyomavirus prevalence inVietnamese non-small-cell lung-cancer

, VNT. Ngo

12:30 - 12:30 13P - Expression of IRAK-1 and EZH-2 in imprints of NSCLC and preneoplastic lesions

, A.-M. Athanassiadou, E. Haini, A. Tsipis, M. Gonidi, P. Athanassiadou; GRK. Hainis

12:30 - 12:30 14P - “Different trend” in multiple primary lung cancer and intrapulmonary metastasis

, G. Che; CNC. Shen

12:30 - 12:30 15P - Clinicopathological analysis of primary pulmonary lymphoepithelioma-like carcinoma

, G. Che; CNC. Shen

12:30 - 12:30 16P - Comprehensive analysis of driver mutations in Chinese squamous cell lung carcinomas bytargeted next-generation sequencing

, D. Tao, S. Yang, X. Han, D. Wu, N. Zhang; CNY. Shi

12:30 - 12:30 17P - Identifying the genetic landscape of squamous cell carcinoma (SCC) and adenosquamouscarcinoma (ASC) of the lung using next-generation sequencing (NGS)

, L. Balabanski, D. Toncheva, G. Kurteva, D. Damyanov, P. Chilingirov; BGN. Chilingirova

12:30 - 12:30 18P - Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as serum marker of bonemetastases from non-small cell lung cancer (NSCLC) and breast cancer. Preliminary results

, A. Del Conte, F. Mazza, S. Basso, G. Chiara; ITF. Lumachi

12:30 - 12:30 19P - Fine needle aspiration cytology of thymic epithelial neoplasms: A cytologic-histologiccorrelation analysis from a referral institution



, PHF.J. Templo

12:30 - 12:30 PREVENTION, EARLY DETECTION, EPIDEMIOLOGY, TOBACCO CONTROL

12:30 - 12:30 25P - A common BIM deletion polymorphism was associated with the risk of lung cancer in aChinese population

, CNX. Jing

12:30 - 12:30 27P - Characteristics of lung cancer diagnosed with low dose chest CT screening

, C. Lee; KRS. Choi

12:30 - 12:30 28P - Sex differences in presentation, management and prognosis of Moroccan patients with nonsmall cell lung carcinoma: A retrospective analysis of 224 cases

, L. Boudahna, Z. Benbrahim, S. Arifi, N. Mellas; MAL. Amaadour

12:30 - 12:30 29P - The risk of lung cancer among women who start smoking as teenagers

, NGM. Tagbarha

12:30 - 12:30 30P - The beliefs, orientation, knowledge, understanding, attitudes and treatment access to lungcancer amongst rural men in Nigeria

, NGM. Tagbarha

12:30 - 12:30 31P - Plasma CRABP2 in patients with non-small cell lung cancer

, H.-Y. Lee, S.-J. Lee, W.J. Kim, Y. Hong, E.J. Lee; KRS.-S. Han

12:30 - 12:30 32P - Epidemiology, treatment patterns and survival outcome in patients of advanced stageinoperable lung cancer: A tertiary cancer care centre analysis

, M. Pant, S. Singh; IND. Kumar

12:30 - 12:30 33P - Idiopathic pulmonary fibrosis as a poor prognostic factor in lung cancer patients

, S. Um, M.-S. Roh; KRC. Son

12:30 - 12:30 TRANSLATIONAL RESEARCH

12:30 - 12:30 41P - The comparative estimation of TUBB3 expression in non-small-cell lung carcinoma andadjacent lung tissue

, I. Mamichev, E. Dudko, A. Grishanina, R. Ramanauskaite, N. Vichljantzeva, S. Tjulandin, B.T. BogushPolotsky, M. Davydov; RU

12:30 - 12:30 42P - Biological role of prognostic microRNAs (miRNAs) in squamous lung carcinoma (SCC) cells

, M. Skrzypski, G. Stasioj, J. Bigda; PLM. Filipska

12:30 - 12:30 43P - miR31-3p expression in patients with advanced lepidic adenocarcinoma (L-ADC) treatedwith EGFR TKI in IFCT 0401 and 0504 trials

, M. Wislez, C. Vazart, V. Decaulne, J. Mazieres, S. Friard, P. Merle, F. Morin, F. Liebaert, J.R. ThiebautCadranel; FR

12:30 - 12:30 44P - Upregulated miRNA 21 in KRAS mutated patients is related to prognosis in resectablenon-small cell lung cancer

, S. Calabuig-Fariñas, E. Jantus-Lewintre, D. Montaner, E. Escorihuela, A. Blasco, R. Guijarro,S. GallachC. Camps; ES



12:30 - 12:30 45P - MicroRNA expression profiling in lung cancer and normal tissue using massively parallelsequencing technique

, S.-Y. Song, K.-H. Lim, S.-J. Lee, S.-S. Han, W.J. Kim; KRH.-Y. Lee

12:30 - 12:30 46P - Antitumor efficacy of the double suicide genes in lung cancer cells

, G. Che; CNC. Shen

12:30 - 12:30 47P - Pharmacogenetics & treatment outcome in cancer patients receiving radio-chemotherapy

, V. Chauhan, D. Parmar; INS. Yadav

12:30 - 12:30 48P - Development of resistance models to tyrosine kinase inhibitors (TKIs) in patient-derivedxenograft models (PDXs) of lung adenocarcinoma with epidermal growth factor receptor (EGFR)mutations

, S. Sakashita , T. Wang , N.-A. Pham , M. Li , G. Liu , M. Tsao ; ON/CA, CAE. Stewart1 1 1 1 1 1 2 1 2

12:30 - 12:30 49P - Synergistic effect of histone deacetylase inhibitor in combination with epidermal growthfactor receptor tyrosine kinase inhibitor in EGFR-TKI resistant non-small cell lung cancer celllines

, N. Zhang, J. Yao, Y. Shi; CNX. Han

12:30 - 12:30 50P - Enumeration and molecular characterization of circulating tumor cells in lung cancerpatients using the GILUPI CellCollector, an effective in vivo device for capturing CTCs

, T. Gorges, N. Penkalla, B. Nowack, T. Schalk, S. Riethdorf, K. Lücke, K. Pantel, T.N. ScheumannKrahn, C. Schumann; DE

12:30 - 12:30 51P - Gef gene: A new suicide gene therapy for non-small cell lung cancer

, R. Hernández, G. Perazzoli, J. Oliver, L. Cabeza, C. Jiménez-Luna, M. Leiva, J.A. Rama BallesterosJiménez, J. Prados; ES

12:30 - 12:30 52P - Multiparameter ploidy profiling: A powerful tool to investigate the genomics of diploid tumorpopulations

, S. Rau , V. Perrina , M. Barrett , C. Ruiz , L. Bubendorf ; CH, AZ/UST. Lorber1 1 1 2 1 1 1 2

12:30 - 12:30 IMAGING AND STAGING

12:30 - 12:30 55P - Proposed new simple criteria of clinical multiple primary lung cancers

, K. Suzuki, K. Takamochi, S. Oh; JPT. Matsunaga

12:30 - 12:30 56P - FDG PET/CT for evaluation of mediastinal lymph node staging using FDG uptake andvolumetric CT histogram in non-small cell lung cancer

, S.M. Lee, J.-H. Lee; KRJ.W. Lee

12:30 - 12:30 SCLC

12:30 - 12:30 57P - Inhibition of the focal adhesion kinase has anti-tumoral effect in small-cell lung cancer celllines

, M. Lecocq , B. Detry , L. Maha , P.P. Massion , Y. Sibille , C. Pilette , S. Ocak ; BE, F. Aboubakar1 1 1 1 2 1 1 1 1

TN/US2

12:30 - 12:30 58P - Radiation therapy (RT) in the palliative treatment of metastatic small cell lung cancer (SCLC)

, I. Ivanova, I. Gulidov, Y. Mardynsky, A. Zolotkov, D. Gogolin, L. Kursova; RUY. Ragulin



12:30 - 12:30 EARLY STAGE NSCLC

12:30 - 12:30 66P - Prognostic classification of lung adenocarcinoma by integrated miRNA-mRNA expressionprofiles

, M. Pintilie , N. Liu , J. McPherson , M. Tsao ; ON/CA, CAS. Tam1 1 1 2 2 1 2

12:30 - 12:30 67P - mRNA expression level of lymphangiogenesis-associated genes in early-stage non-smallcel lung cancer

, M. Kozlowski, W. Laudanski, J. Kisluk, J. Niklinski; PLO. Kowalczuk

12:30 - 12:30 68P - The utility of actinin-4 protein overexpression as a predictive biomarker for therapeuticeffect of adjuvant chemotherapy to the resected lung adenocarcinoma

, Y. Fujiwara , T. Kakuya , K. Tsuta , S. Watanabe , W. Huang , T. Yamada , H. AsamuraH. Shiraishi1 1 1 1 1 2 1

, Y. Ohe , K. Honda ; JP, TW1 1 1 1 2

12:30 - 12:30 69P - The impact of genetic alteration on recurrence in patients with resected stage I non-smallcell lung cancer

, E.Y. Heo, S.S. Park, Y.S. Park, Y.W. Kim, D.K. Kim; KRH.S. Chung

12:30 - 12:30 70P - Prognostic role of T-regulatory cells in completely resected early stage non-small cell lungcarcinoma

, H. Abali , A. Fndkcoglu , T. Canpolat , A. Besen , A. Sumbul , H. Mertsoylu , A. Sedef , O.F. Kose1 1 1 1 1 1 2 1

Ozyilkan ; TR, TN1 1 2

12:30 - 12:30 71P - Outcome after SBRT for potentially operable NSCLC patients

, H. Peulen, H. van Tinteren, M. Wouters, J.-J. Sonke, P. Baas, E. Smit, J. Belderbos; NLM. Rossi

12:30 - 12:30 72P - Occurrence of significant tumor volume changes during stereotactic body radiation therapyfor lung cancer

, L. Moretti, Y. Jourani, T. de Brouwer, P. Van Houtte; BEF. Charlier

12:30 - 12:30 73P - Outcome of early-stage lung cancer treated with stereotactic body radiotherapy (SBRT)

, J. Chan, A. Pope, A. Haridass, A. Baker, S. Meara, R. Clements, A. Crabtree, H. Wong,M. AlameddineC. Eswar; UK

12:30 - 12:30 74P - Does a higher surgical resection rate in lung cancer lead to a higher rate of post-operativemulti-station N2 disease?

, S. Britton, H. Al-Najjar, P. Crosbie, P. Bishop, M. Jones, P. Krysiak, K. Rammohan, R. Shah,M. EvisonR. Booton; UK

12:30 - 12:30 75P - Adequacy of lymph node sampling during surgical resection of lung cancer at a regional UKthoracic surgical centre 2011-2013

, S. Britton, H. Al-Najjar, P. Crosbie, M. Jones, P. Bishop, P. Krysiak, K. Rammohan, R. Shah,M. EvisonR. Booton; UK

12:30 - 12:30 76P - Result of the 6-minute walk test is an independent prognostic factor of surgically treatednon-small cell lung cancer

, M. Badocha, D. Wnuk, A. Mosiewicz, W. Rzyman; PLT. Marjanski

12:30 - 12:30 77P - Post-operative outcomes in non-small cell lung cancer patients with mild to moderate stagechronic obstructive pulmonary disease



, S. Marumo, S. Kumagai, K. Yamanashi, J. Tokuno, R. Sumitomo, T. Shoji, C. Huang, M. Fukui;R. ItotaniJP

12:30 - 12:30 78P - Examination of prognostic factors in cases receiving UFT as postoperative adjuvantchemotherapy for lung cancer

, R. Yoneyama, M. Kakihana, N. Kajiwara, T. Ohira, N. Ikeda; JPK. Nawa

12:30 - 12:30 79P - Volume changes with hypo-fractionated radiotherapy in early lung cancer: Time trends &outcomes

, A. Tibdewal, S. Ghosh Laskar, S. Chaudhari, J.P. Agarwal; INR. Pathak

12:30 - 12:30 80P - Role of treatment in international differences in one-year mortality from early stagenon-small cell lung cancer: A tentative answer from the International Cancer BenchmarkingPartnership study

, M. Peake , J. Butler , M. Coleman , W. Evans , E. Jakobsen , M. Boyer , T. JohannesenT. Solomon1 1 1 1 2 3 4

, B. Rachet ; UK, ON/CA, DK, NSW/AU, NO5 1 1 2 3 4 5

12:30 - 12:30 LOCALLY ADVANCED NSCLC

12:30 - 12:30 84P - Trimodality therapy including radical resection for pancoast tumors: T4 is not acontraindication for radical surgery

, R. Waseda, T. Klikovits, O. Foesleitner, S. Zoechbauer-Mueller, K. Dieckmann, H. Prosch, R.M. HodaPirker, W. Klepetko; AT

12:30 - 12:30 85P - Review of radical radiotherapy +/- chemotherapy for stage III NSCLC

, R. Evans, E. Rees, C. Bullock; UKM. Button

12:30 - 12:30 86P - Can concurrent chemo-radiation be delayed by induction chemotherapy in the curativetreatment of stage III non-small cell lung carcinoma?: A pooled analysis

, A. Garant , M. Almajed , S. Faria , S. Owen , M. Duclos , L. Ofiara , J. Gruber , V.C. Guilbault1 2 1 1 1 1 1 1

Hirsh , N. Kopek ; QC/CA, CA1 1 1 2

12:30 - 12:30 87P - What to do for the treatment of non small cell lung cancer (NSCLC) with a single mediastinallymph node involvement (N2a disease) in developing countries?

, H. Hafizi, A. Mezini, D. Xhemalaj, I. Skenduli; ALF. Caushi

12:30 - 12:30 88P - Omission of elective nodal irradiation has no impact on isolated elective nodal failure andsurvival outcomes in stage III non-small-cell lung cancer patients treated with definitiveconcurrent chemoradiotherapy


12:30 - 12:30 89P - Clinical factors of nodal upstaging in pathologic N1 or N2 non-small cell lung cancer

, S.W. Sung, K.S. Kim, J.K. Park; KRY. Moon

12:30 - 12:30 90P - Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin in inoperable stageIII non-small cell lung cancer

, F. Kose , A. Sedef , O. Dogan , C. Parlak , A. Besen , A. Sumbul , A. Sezer , A.H. Mertsoylu1 2 2 2 2 2 2 2

Fndkcoglu , S. Muallaoglu ; TN, TR2 2 1 2

12:30 - 12:30 91P - Definitive concomitant radiochemotherapy (RCT) treatment for locally advanced (LA) nonsmall cell lung cancer (NSCLC): Evaluation of hematological and esophageal toxicity in theRadiation Oncology Department of University of Florence experience



, D. Scartoni, I.F. Furfaro, G. Simontacchi, C. De Luca Cardillo, B. Agresti, C. Talamonti, L. Livi;V. ScottiIT

12:30 - 12:30 92P - Social deprivation and radical treatment of stage III NSCLC

, R. Evans, C. Bullock, E. Rees; UKM. Button

12:30 - 12:30 93P - The clinical characteristics of 50 patients with radiation-induced pneumonia

, Q. Zhang, X. Wang; CNR. Liu

12:30 - 12:30 94P - Lung cancer in women, a different disease: Survival differences by sex

, S.T. Tokluoglu, M. Kös, K. Silay, S. Akinci, B. Oksuzoglu, N. Alkis; TRA. Ulas

12:30 - 12:30 ADVANCED NSCLC

12:30 - 12:30 111P - Ceritinib treatment of patients (Pts) with ALK-rearranged (ALK+) non-small cell lung cancer(NSCLC) and brain metastases: ASCEND-1 trial experience

, R. Mehra , D. Tan , E. Felip , T. Szczudlo , S. Sutradhar , K. Rodriguez Lorenc , A. ShawD.-W. Kim1 2 3 4 5 5 5

; KR, PA/US, SG, ES, NJ/US, US6 1 2 3 4 5 6

12:30 - 12:30 112P - Efficacy and safety of imprime PGG, a novel innate immune modulator, in combination withbevacizumab (Bev), carboplatin and paclitaxel for the 1st-line treatment of stage IV NSCLC

, W. Engel-Riedel , F. Schneller , M. Wolf , W. Schuette , J. Lowe , P. Mattson , M. GarganoA. Braun1 2 2 2 2 1 1

, M. Patchen , R. Huhn ; US, DE1 1 1 1 2

12:30 - 12:30 113P - Anlotinib as third-line treatment in patients with refractory advanced non-small cell lungcancer: A multicentre, randomized, double-blind, placebo-controlled, phase II trial (NCT01924195)

, K. Li, Y. Zhao, B. Li, Y. Cheng, J. Zhou, Y. Lu, Y. Shi, Z. Wang, L. Jiang; CNB. Han

12:30 - 12:30 114P - A phase 1b study of anti-DLL4 (delta-like ligand 4) antibody demcizumab (DEM) withpemetrexed (PEM) and carboplatin (CARBO) in patients with 1st-line non-squamous NSCLC

, M. McKeage , D. Kotasek , B. Markman , M. Hidalgo , M. Millward , M. Jameson , D.J. Dupont1 2 3 3 4 5 2

Harris , R. Stagg , B. Hughes ; CA/US, NZ, AU, ES, WA/AU, US, QLD/AU2 6 7 1 2 3 4 5 6 7

12:30 - 12:30 115P - KIF5B & CCDC6 RET in lung cancer: Clinical insights and response to personalized basedtherapy

, A. Moore, M. Gottfried, R. Katznelson, H. Nechushtan, M. Wolner, V. Neiman, L.M. SarfatySoussan-Gutman, A. Dvir, N. Peled; IL

12:30 - 12:30 116P - Clinical characteristics and response to EGFR TKI in never smoker squamous lung cancer

, S. Young, E.H. Tan, D. Lim, G.S. Tan, A. Jain, W. Zeng, T. Lim, A. Takano, D. Tan; SGS. Ee

12:30 - 12:30 117P - German country-wide surveys from 2012 and 2014 about EGFR mutational testingalgorithms adopted by medical doctors in patients with NSCLC

, D. Ukena, S. Radke, A. Freitag, S. Hörnig; DEH. Ostermann

12:30 - 12:30 118P - Erlotinib as first-line treatment for patients with advanced EGFR mutation-positivenon-small-cell lung cancer: Phase IIIB study

, B. Perin, M. Cekic, M. Rancic, V. Kovcin, Z. Andric, Z. Murtezani, D. Jovanovic, M. Velinovic, M.B. ZaricMarkovic; RS

12:30 - 12:30 119P - Reversible versus irreversible EGFR tyrosine-kinase inhibitors for non-small-cell lungcancer (NSCLC): A preclinical and pharmacokinetic comparison



, T. Friess , D. Shames , M. Wright , C. Hop ; CA/US, DEB. Liederer1 2 1 1 1 1 2

12:30 - 12:30 120P - Is switch maintenance therapy mandatory for EGFR mutated patients initiated onchemotherapy?

, INR. Roy

12:30 - 12:30 121P - Serum carcinoembryonic antigen levels predicts the efficacy of EGFR-TKI in non-small celllung cancer harboring EGFR mutations

, B. Han, B. Jin, Y. Lou, R. Li, X. Zhang, S. Hu; CNY. Zhang

12:30 - 12:30 122P - Icotinib as first-line treatment for elderly patients with EGFR 19 or 21 mutation in advancedNSCLC: A phase-IV, open-label, single-arm study

, C. Shi, J. Qian, R. Li; CNB. Han

12:30 - 12:30 123P - Outcomes of octogenarian (80 yo) patients with advanced non-small cell lung cancer(NSCLC): A single institution experience from The Christie Hospital

, J. Chiramel, N. Flaum, A. Lewis, Y. Summers, P. Taylor, A. Chittalia, H. Sheikh, F. Blackhall,M. HowellR. Califano; UK

12:30 - 12:30 124P - Platinum based chemotherapy for the treatment of elderly patients with metastatic nonsmall cell lung carcinoma: A retrospective analysis of a single institution


12:30 - 12:30 125P - A prospective randomized phase III study of palliative chemotherapy versus bestsupportive care in elderly patients with advanced non-small cell lung cancer: Survival analysisand ECOG performance status regression analysis

, A. Kapoor, A. Kalwar, S. Narayan, M. Singhal, A. Kumar, S. Lal, R. Nirban, M.N. KumarParamanandhan, R. Purohit; IN

12:30 - 12:30 126P - Outcomes over a decade in stage IV non-small cell lung cancer (NSCLC): The ClatterbridgeCancer Centre experience

, H. Wong, E. Marshall; UKC. Escriu

12:30 - 12:30 127P - A prospective randomized phase III study evaluating quality of life in advanced non-smallcell lung cancer receiving platinum based chemotherapy combination in old versus new standardchemotherapy regimen

, A. Kapoor, S. Dutta; INA. Rungta

12:30 - 12:30 128P - Comparison of efficacy of pemetrexed plus platinum and non-pemetrexed plus platinum as1st line chemotherapy in EGFR wild type non-squamous NSCLC

, S.Y. Lee, J.S. Kim; KRE.J. Kang

12:30 - 12:30 129P - Effectiveness of first-line pemetrexed plus platinum for advanced nonsquamous non-smallcell lung cancer

, M. Luis, N. Amaral, M. Cassiano Neves, C. Camacho, A. Rodrigues, I. Pousa, J. Oliveira, I.M. BrandãoAzevedo, M. Soares; PT

12:30 - 12:30 130P - Maintenance pemeterexed in NSCLC - outcome analysis from a tertiary care center

, K. Prabhash, V. Noronha, A. Joshi; INA. Pandey

12:30 - 12:30 131P - Duration and tolerance of maintenance pemetrexed (mPem) treatment for advancednon-small cell lung cancer

, E. Josephides, E. Karapanagiotou, A. Montes, J. Spicer, R. Lal; UKP. Charlton



12:30 - 12:30 132P - Weekly carboplatin and paclitaxel in advanced non-small cell lung cancer: Good responserate but poor overall survival in a "real world" population

, V. Volk , U. Mey , P. Brossart , R. Von Moos , R. Cathomas ; CH, DEM. Mark1 2 1 2 1 1 1 2

12:30 - 12:30 133P - An estimation of the population-based survival benefit of first-line chemotherapy for lungcancer

, W. Ng, S. Jacob, G. Delaney, M. Barton; AUV. Do

12:30 - 12:30 134P - Effect of haematological adverse effects occuring during chemotherapy on response totreatment and progression free survival in advanced NSCLC

, E. Fouad, K. Nasr, H. El-Ghazaly, A. Adel; EGA. Nagy

12:30 - 12:30 135P - Significance of thyroid transcription factor 1 expression in patients with nonsquamousNSCLC treated with pemetrexed based chemotherapy

, A. Velastegui Ordoñez, R. Martínez Cabañes, A. Rosero, L. Ruiz-Giménez, J.C. Cámara, S.X. MielgoHernando, A. Hurtado, C. Olier, C. Jara; ES

12:30 - 12:30 136P - TTF1 expression in advanced non-small cell lung cancer: Impact on survival outcome

, T. Al-fayea , W. Abozeed , A. Alzahrani , M. Farooq , W. Darwish , A. Almadani , E.S. Elsamany1 2 1 2 2 2 2

Bukhari ; EG, SA2 1 2

12:30 - 12:30 137P - Risk factors for skeletal-related events in patients with non-small cell lung cancer patientswith bone metastases

, A. Bilici, S.T. Tokluoglu, S. Akinci, K. Silay, F. Paksoy Turkoz, A. Durnali, B. Oksuzoglu, N. Alkis;A. UlasTR

12:30 - 12:30 METASTASES TO AND FROM THE LUNG

12:30 - 12:30 146P - Stereotactic ablative radiotherapy (SART) of lung lesion in oligometastatic patients: Theimportance of high doses delivery

, I.F. Furfaro, D. Scartoni, L. Paoletti, M. Loi, S. Russo, S. Pallotta, B. Agresti, P. Bastiani, L. Livi;V. ScottiIT

12:30 - 12:30 147P - Different metastatic pattern according to the EGFR mutational status in a cohort of lungadenocarcinomas (ADCs): A single-institution report

, T. Franchina, A. Picone, G. Ferraro, M. Picciotto, M. Zanghì, V. Franchina, V. Adamo; ITA. Russo

12:30 - 12:30 148P - Incidence of brain metastases identified upon initial diagnosis in different histologicaltypes of lung cancer: A single department experience

, F. Popovic, I. Markelic, S. Kukulj; HRG. Drpa

12:30 - 12:30 149P - Presentation and patterns of care of lung cancer patients with brain metastasis at a tertiarycare centre In India

, R. Pathak, S. Ghosh Laskar, K. Prabhash, G. Karimundackal, J.P. Agarwal; INA. Tibdewal

12:30 - 12:30 150P - Usefulness of lung palpation through thoracotomy for metastasectomy in patients withnon-imaged pulmonary nodules

, F. Mazza, A. Del Conte, G. Chiara, S. Basso; ITF. Lumachi

12:30 - 12:30 151P - Post-treatment effects of lung cancer on spinal fracture

, NGM. Tagbarha



12:30 - 12:30 152P - Transarterial chemoembolisation using drug-eluting microspheres DEM-TACE in lungcarcinoma metastases to the liver in humans

, K. Pyra, T. Jargieo, M. Szczerbo Trojanowska, P. Chabros, J. Milanowski; PLB. Rybacka-Chabros

12:30 - 12:30 153P - Factors affecting survival in patients with pulmonary metastases from colorectal cancerwith previously resected liver metastases who underwent lung metastasectomy


12:30 - 12:30 154P - Surgical treatment of synchronous lung metastasis in patient with osteosarcomas and softtissue sarcomas

, Y. Ragulin, A. Starodubtcev, A. Kurilchik, V. Usachev, A. Zubarev, V. Ivanov; RUE. Smolenov

12:30 - 12:30 MESOTHELIOMA

12:30 - 12:30 157P - Pleural malignant mesotheliomas over-express PD-L1

, J. Xiu , S. Millis , Z. Gatalica ; CH, AZ/US, USA. Voss1 2 2 3 1 2 3

12:30 - 12:30 158P - New therapeutic approach for mesothelioma

, M. Takahashi, Y. Ino, T. Todo, N. Ikeda; JPY. Sakata

12:30 - 12:30 159P - Impact of maintenance pemetrexed in the management of non-progressing malignantmesotheliomas after standard fist-line chemotherapy: A single institution experience

, A. Russo, A. Picone, G. Ricciardi, F. Raiti, A. Scimone, G. Chiofalo, G. Toscano, V.T. FranchinaAdamo; IT

12:30 - 12:30 160P - Pretreatment serum albumin level is an independent prognostic biomarker in malignantpleural mesothelioma

, P. Stockhammer , Y. Dong , M. Jakopovic , L. Brcic , B. Dome , B. Hegedus , M.T. Klikovits1 1 1 2 2 1 1

Samarzija , W. Klepetko , M. Hoda ; AT, HR2 1 1 1 2

12:30 - 12:30 161P - Long-term survival in adults suffered from malignant mesothelioma and pulmonarytuberculosis combined - observational study

, A. Oszywa-Chabros, J. Milanowski; PLB. Rybacka-Chabros

12:30 - 12:30 162P - Statin use and survival in malignant pleural mesothelioma (MPM)

, A. Navarro, A. Martinez, P. Martinez, C. Ortiz, L. Fariñas, E. Felip; ESS. Cedres

12:30 - 12:30 163P - Solitary fibrous tumors of the pleura: Surgical treatment, analysis of our cases fromSeptember 1999 to August 2014

, L. Lisha, D. Argjiri, F. Kokici, A. Cami, G. Cerga, P. Hyska, P. Kapisyzi; ALF. Gradica

12:30 - 12:30 MISCELLANEOUS

12:30 - 12:30 164P - Quality in lung cancer care: The Victorian Lung Cancer Registry pilot initial report

, S. Evans, M. Senthuren, P. McLaughlin, J. McNeil; VIC/AUR. Stirling

12:30 - 12:30 165P - Preoperative positron emission tomography fractal biopsy of thymic epithelial neoplasm

, G. Felloni, M. Salgarello, A. Viti, A. Bianchi, A. Terzi; ITL. Bertolaccini

12:30 - 12:30 166P - Accuracy of pleural carcinoembryonic antigen (CEA) assay in patients with benign andmalignant pleural effusions requiring thoracentesis




12:30 - 12:30 167P - Improved quality of life of patients with malignant pleural effusion who underwentvideo-assisted minimally invasive thoracentesis and talc pleurodesis


12:30 - 12:30 168P - Malignant pleural effusion biomarkers as predictor for chemical pleurodesis success

, EGS. Alsayed

12:30 - 12:30 169P - Incidence of pain among lung cancer patients hospitalized in Palliative Care Department ofComprehensive Cancer Center – Vratsa for the period 2009 – 2013

, S. Aleksandrova, D. Yordanova; BGN. Yordanov

12:30 - 12:30 170P - Anterior mediastinal mass case series

, P. Shivanna, S. Kumar, D. Pandey, S.V.S. Deo, N.K. Shukla; INP. Ramanathan

12:30 - 12:30 171P - Surgical treatment of mediastinal neurogenic tumors and dumbell syndrome in adults: A12-year experience, January 2002 to January 2014


12:30 - 12:30 172P - Post-surgical follow-up for non-small cell lung carcinoma (NSCLC): Challenging currentpractice

, M. Haris, I. Hussain, S. Ghosh; UKF. Iqbal

12:30 - 12:30 173P - Misdiagnosis of lung tuberculosis leads to delaying in lung cancer diagnosis andtreatment: Time to use anti-tuberculosis treatment judiciously

, INR. Devgan

12:30 - 12:30 174P - Mesenchymal tumors of the mediastinum and the role of surgery in their treatment

, H. Hafizi, A. Mezini, I. Skenduli, D. Xhemalaj; ALF. Caushi

12:30 - 12:30 175P - A novel technique for the management of reccurent malignant pericardial effusions

, D. Patrini, B. Adams, D. Lawrence; UKN. Panagiotopoulos

12:30 - 12:30 176P - Feasiblity of endoscopic transumbilical anatomic lobectomy in a canine model

, TWY.-H. Liu

12:30 - 12:30 TRIALS IN PROGRESS

12:30 - 12:30 95TiP - A phase 3, randomised, double-blind, placebo-controlled, International study of MEDI4736in patients with locally advanced, unresectable, stage 3 NSCLC who have not progressedfollowing platinum-based, concurrent chemoradiation therapy (PACIFIC)

, N. Iannotti , M. Salamat , D. Jayawardene , M. Ballas , P. Stockman , S. Antonia ; B. Creelan1 1 2 3 3 4 1 1

FL/US, KS/US, MD/US, UK2 3 4

12:30 - 12:30 138TiP - Ceritinib in patients (pts) with anaplastic lymphoma kinase (ALK)-rearranged (ALK+)non-small cell lung cancer (NSCLC) metastatic to the brain and/or leptomeninges: The phase IIASCEND-7 study

, F. Barlesi , E. Bertino , D.-W. Kim , M. van den Bent , H. Wakelee , P. Wen , P. CazorlaL. Chow1 2 3 4 5 6 7

Arratia , J. Shen , F. Branle ; US, FR, OH/US, KR, NL, CA/US, MA/US, NJ/US, CH8 8 9 1 2 3 4 5 6 7 8 9



12:30 - 12:30 139TiP - Phase 2, open-label, international, non-comparative study of MEDI4736 in patients withlocally advanced or metastatic, PD-L1+, stage 3B–4 NSCLC who have received 2 prior systemictreatment regimens (ATLANTIC)

, M. Garassino , J. Vansteenkiste , M. Ballas , D. Jayawardene , P. Stockman , J. Powderly ,J. Gray1 2 3 4 4 5 6

N. Rizvi ; FL/US, IT, BE, MD/US, UK, NC/US, NY/US7 1 2 3 4 5 6 7

12:30 - 12:30 140TiP - AURA3 design: a randomised, Phase III study of AZD9291 versus second-linechemotherapy for patients (pts) with EGFR-TKI-resistant (T790M) advanced non-small cell lungcancer

, V. Papadimitrakopoulou , S. Ghiorghiu , A. Templeton , T. Mok ; CN, TX/US, UKY.-L. Wu1 2 3 3 1 1 2 3

12:30 - 12:30 141TiP - AZD9291, a third generation EGFR inhibitor, versus gefitinib or erlotinib intreatment-naïve patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring anEGFR-TKI-sensitising mutation (EGFRm): A randomised, phase III study (FLAURA)

, Y. Rukazenkov , K. Thomas , J.-C. Soria ; GA/US, UK, FRS. Ramalingam1 2 2 3 1 2 3

12:30 - 12:30 142TiP - Randomized, double-blind, placebo-controlled trial of evofosfamide (TH-302) incombination with pemetrexed in advanced non-squamous non-small cell lung cancer

, C. Belani , S. Novello , J. von Pawel , T. Csoszi , S. Orlov , S. Kroll , T. Pearce ; J. Goldman1 2 3 4 5 6 1 2 1

CA/US, US, IT, DE, HU, RU2 3 4 5 6

12:30 - 12:30 143TiP - SPECTAlung: Screening patients with thoracic tumors for efficient clinical trial access

, J. Menis , J. Adam , R. Dziadziuszko , B. Hasan , L. Lacroix , S. Peters , D. Lacombe , M.B. Besse1 2 1 3 2 1 4 2

O'Brien , R. Stahel ; FR, BE, PL, CH, UK5 4 1 2 3 4 5

12:30 - 12:30 144TiP - Open-label single-arm phase IV study to assess the efficacy and safety of afatinib assecond-line therapy for patients with locally advanced or metastatic non-small cell lung cancer(NSCLC) harbouring common epidermal growth factor receptor (EGFR) mutations (Del19 and/orL858R) who have failed first-line treatment with platinum-based chemotherapy

, H. Jones , A. Cseh , R. Gaafar ; TH, UK, AT, EGS. Thongprasert1 2 3 4 1 2 3 4

14:30 - 16:00 Approaches to TKI resistance Room A

Chair: B. Besse, FR; T. Mok, CN

14:30 - 14:50 Novel definition of TKI resistance: Clinical versus molecular

, MA/USG. Oxnard

14:50 - 15:10 How to target T790M mutation?

, CNT. Mok

15:10 - 15:30 Management of EGFR-TKI resistance by local therapy, chemotherapy and antiangiogenesis

, DEM. Reck

15:30 - 15:50 Treatment options for ALK-TKI resistance

, KRD.-W. Kim




14:30 - 16:00 New treatment avenues Room B

Chair: D. De Ruysscher, BE; S. Peters, CH

14:30 - 14:45 60O - Analysis of local recurrences following stereotactic ablative radiotherapy (SABR): Data froma large institutional database

, F. Lagerwaard, B. Slotman, M. Dahele, S. Senan; NLN.E. Verstegen

14:45 - 15:00 61O - Outcome of surgical salvage for local failures following stereotactic ablative radiotherapy(SABR)

, F. Lagerwaard, M.A. Paul, E. Smit, M.I.M. Versteegh, J.J.A. Joosten, B. Slotman, S.N.E. VerstegenSenan; NL


, USE. Vallières

15:15 - 15:30 81O - Erlotinib as neoadjuvant treatment in endobronchial ultrasound confirmed stage IIIA-N2non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)mutation (Exon 19 or 21) (NCT01217619, ESTERN)A prospective, single arm, phase II clinical trial

, L. Xiong, J. Sun, R. Li, Y. Lou, Y. Zhang, A. Gu, L. Jiang, J. Shi; CNB. Han

15:30 - 15:45 96O - Determining the prevalence of EGFR mutations in Asian and Russian patients (pts) withadvanced non-small-cell lung cancer (aNSCLC) of adenocarcinoma (ADC) and non-ADChistology: IGNITE study

, S. Tjulandin , K. Hagiwara , N. Normanno , L. Wulandari , L. Konstantin Konstantinovich , A.B. Han1 2 3 4 5 2

Hudoyo , M. Ratcliffe , R. McCormack , M. Reck ; CN, RU, JP, IT, ID, UK, DE5 6 6 7 1 2 3 4 5 6 7


, DEW. Eberhardt

16:30 - 18:00 Locoregional treatment for oligometastatic lung cancer Room B

Chair: U. Ricardi, IT; P. Van Schil, BE

16:30 - 16:50 Management of oligometastatic lung cancer and brain metastasis

, DEF. Wenz

16:50 - 17:10 Surgery for oligometastatic lung cancer and liver or adrenal metastases

, BEP. Van Schil

17:10 - 17:30 Stereotactic ablative RT for oligometastatic lung cancer

, NLS. Senan

17:30 - 17:50 Surgery for synchronous lung tumours

, ITG. Veronesi


16:30 - 17:45 Advanced NSCLC Room V

Chair: E. Felip, ES; S. Novello, IT; J. Vansteenkiste, BE



16:30 - 16:30 104PD - Phase 2 study of nivolumab (anti-programmed death-1 [PD-1]) in patients (pts) withadvanced, refractory squamous (SQ) non-small cell lung cancer (NSCLC)

, N. Rizvi , H. Lena , J. Wolf , J. Mazieres , S. Antonia , E. Minenza , D. Planchard , B.G. Zalcman1 2 1 3 1 4 5 1

Lestini , S. Ramalingam ; FR, NY/US, DE, FL/US, IT, NJ/US, GA/US6 7 1 2 3 4 5 6 7

16:30 - 16:30 105PD - TG4010 immunotherapy combined with first-line chemotherapy in advanced non-smallcell lung cancer (NSCLC). Phase 2b results of the TIME study

, J. Nemunaitis , Z. Papai , H. Lena , D. Genet , C. Louis , M. Cobo , Y. Al Farhat , B.E. Quoix1 2 3 1 1 4 5 3

Marie-Bastien , J.M. Limacher ; FR, TX/US, HU, BE, ES1 1 1 2 3 4 5


, BEJ. Vansteenkiste


16:55 - 16:55 106PD - EGFR mutation detection in plasma of lung tumor patients in the absence of contributivetissue is a relevant alternative for prescription of tyrosine kinase inhibitors in a routine clinicalsetting

, A. Vallée, P. Masson, T. Pigeanne, H. Lacroix; FRM. Denis

16:55 - 16:55 1PD - An integrative analysis of the putative gefitinib-resistant genes in a lung cancer cell linemodel system

, M. Liu, S. Wang, X. Qian, G. Lv, L. Ma, C. Zeng, Y. Shi; CNX. Han


, ESE. Felip


17:20 - 17:20 107PD - Afatinib (A) plus paclitaxel (P) following progression on A monotherapy in patients (pts)with metastatic non–small-cell lung cancer (NSCLC) who previously benefited from erlotinib(E)/gefitinib (G): A global randomised phase III trial – LUX-Lung 5 (LL5)

, J. Yang , K. Park , V. Chand , B. Wang , D. Planchard , T. Darweesh ; DE, TW, KR, M. Schuler1 2 3 4 4 5 6 1 2 3

US, FR, EG4 5 6

17:20 - 17:20 108PD - Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advancedsquamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy:LUX-Lung 8 (LL8), a phase III global trial

, E. Felip , M. Cobo , S. Lu , V. Georgoulias , A. Ardizzoni , S. Gadgeel , B. Wang , V.G. Goss1 2 2 3 4 5 6 6

Chand , J.-C. Soria ; ON/CA, ES, CN, GR, IT, US, FR6 7 1 2 3 4 5 6 7

17:20 - 17:20 109PD - Overall survival (OS) with afatinib (A) vs chemotherapy (CT) in patients (pts) with NSCLCharbouring EGFR mutations (mut): Subgroup analyses by race in LUX-Lung 3 (LL3) andLUX-Lung 6 (LL6)

, J. Yang , L. Sequist , N. Yamamoto , C. Zhou , C.-P. Hu , K. O’Byrne , V. Hirsh , T. MokM. Schuler1 2 3 4 5 5 6 7

, Y.-L. Wu ; DE, TW, MA/US, JP, CN, QLD/AU, QC/CA5 5 1 2 3 4 5 6 7


, ITS. Novello




16:30 - 18:00 Medical and surgical oncology Room A

16:30 - 16:45 155O - Chemotherapy of malignant pleural mesothelioma does not preclude use of check-pointblockade

, V. Cecconi, E. Felley Bosco, I. Schmitt-Opitz, W. Weder, R. Stahel, M. van denA. Curioni FontecedroBroek, V. Tischler; CH

16:45 - 17:00 39O - Immune checkpoints score and CD8+ T cells infiltration are independent prognosticbiomarkers in resected NSCLC

, E. Jantus-Lewintre, R. Sirera, S. Calabuig-Fariñas, A. Blasco, R. Guijarro, J. Forteza, C. Camps;M. UsóES


, DEM. Reck

17:15 - 17:30 62O - Thirty and 90-day mortality after lung cancer resection in 2242 patients

, H. Lüders, G. Leschber; DEA. Frick

17:30 - 17:45 53O - Is routine sampling of the inferior mediastinal lymph node stations a necessity forpre-operative mediastinal staging in lung cancer? Results of a large retrospective study of 986surgical resections



16:30 - 18:00 Second ESO Lung Cancer Observatory Room X

Chair: M. Aapro, CH; J. Vansteenkiste, BE

16:30 - 16:45 Screening/surgery advances

, FRD. Grunenwald

16:45 - 17:00 Radiotherapy in extensive disease SCLC (PCI, thoracic RT)

, PLR. Dziadziuszko

17:00 - 17:15 Anti-PD1 and anti-PDL1 strategies in NSCLC, its potential role in NSCLC treatment

, CHS. Peters

17:15 - 17:30 Predictive markers in NSCLC (beyond EGFR / ALK)

, UKK. Kerr

17:30 - 17:45 Long-term lung cancer survivors, patient's needs (patient representative)

04-17-2015



08:00 - 08:50 Heterogeneity in lung cancer: The elephant in the room? Room A

Chair: Y. Yatabe, JP; L. Bubendorf, CH

08:00 - 08:15 Impact of tumour heterogeneity on biomarker testing

, JPY. Yatabe

08:15 - 08:30 Genomic heterogeneity and clonal evolution in NSCLC

, CHL. Bubendorf


08:00 - 08:50 How to deal with multifocal adenocarcinoma? Room W

Chair: J. Shrager, US; E. Felip, ES

08:00 - 08:15 Surgical strategies and planning

, CA/USJ. Shrager

08:15 - 08:30 The role of EGFR TKIs in non-metastatic multifocal adenocarcinoma

, ESE. Felip


08:00 - 08:50 Immunotherapy and translational research Room X

Chair: M. Krebs, UK; J. Corral, ES

08:00 - 08:20 Immune-checkpoint blockade for the treatment of advanced NSCLC

, ESJ. Corral

08:20 - 08:40 The promises and pitfalls of liquid biopsy for the molecular portrait and monitoring of treatmentresponse in NSCLC

, UKM. Krebs




09:00 - 10:30 Functional evaluation early stage lung cancer Room A

Chair: D. Grunenwald, FR

09:00 - 09:20 Cardiopulmonary function testing: What makes sense?

, UKA. Brunelli

09:20 - 09:40 Preoperative risk models: The choice between surgery and stereotactic RT

, UKE. Lim

09:40 - 10:00 Predicted postoperative lung function: How low can we go?

, UKD. Waller

10:00 - 10:20 What functional evaluation before chemoradiation?

, NLJ. Belderbos


09:00 - 10:30 Advanced NSCLC Room C

Chair: K. Kerr, UK; J. Vansteenkiste, BE

09:00 - 09:15 97O - EGFR mutant subset analysis from ARCHER 1009: A randomized double blind phase 3efficacy and safety study of dacomitinib versus erlotinib for the treatment of advanced non-smallcell lung cancer (NSCLC)

, K. O'Byrne , T. Mok , M. Boyer , P. Jänne , Z. Goldberg , C. Mather , I. Taylor , H.L. Paz-Ares1 2 3 4 5 6 6 6

Zhang , S. Ramalingam ; UK, AU, CN, NSW/AU, US, NY/US, GA/US6 7 1 2 3 4 5 6 7

09:15 - 09:30 LBA3 - A phase I study of AZD9291 in patients with EGFR-TKI-resistant advanced NSCLC –updated progression free survival and duration of response data

, M.-J. Ahn , D.-W. Kim , S.-W. Kim , D. Planchard , S. Ramalingam , P. Frewer , M.P. Jänne1 2 2 2 3 4 5

Cantarini , S. Ghiorghiu , J. Yang ; US, KR, FR, GA/US, UK, TW5 5 6 1 2 3 4 5 6


, AUK. O'Byrne

09:45 - 10:00 98O_PR - Targeted therapy for BRAF-mutant lung cancer: Results from the European EURAFcohort study

, M. Bluthgen , E. Smit , J. Wolf , M. Früh , S. Peters , M. Schuler , G. Zalcman , J. MiliaO. Gautschi1 2 3 4 1 1 4 2

, J. Mazieres ; CH, FR, NL, DE2 2 1 2 3 4

10:00 - 10:15 99O - Phase 1/2 study of AP26113 in patients (Pts) with advanced malignancies, includinganaplastic lymphoma kinase (ALK)–positive non-small cell lung cancer (NSCLC): Analysis ofsafety and efficacy at selected phase 2 doses

, S. Gettinger , L. Bazhenova , C. Langer , R. Salgia , K. Gold , A. Shaw , D. Dorer , D.R. Rosell1 2 3 2 4 5 2 2

Kerstein , D..R. Camidge ; ES, US, CA/US, IL/US, TX/US, CO/US2 6 1 2 3 4 5 6


, PLR. Dziadziuszko



09:15 - 10:15 Can adaptive design help to proceed in clinical trials in lung cancer? Room B

Chair: D. Carbone, US; E. Felip, ES

09:15 - 09:25 Introduction and first vote

09:25 - 09:45 5 reasons pro

, FRB. Besse

09:45 - 10:05 5 reasons contra

, BEM. Buyse

10:05 - 10:15 Second vote and conclusions

11:00 - 12:30 Quality management in thoracic oncology Room W

Chair: A. Rich, UK; J.-P. Sculier, BE

11:00 - 11:20 Guidelines in thoracic oncology: A European point of view

, BEM. Paesmans

11:20 - 11:40 National and local care for patients with thoracic malignancies across Europe

, UKA. Rich

11:40 - 12:00 Quality of training in thoracic oncology: The HERMES programme

, DEF. Gamarra

12:00 - 12:20 The European Initiative for Quality Management in Lung Cancer Care (EIQMLCC)

, DET. Blum




11:00 - 12:30 New WHO classification: Putting it into practice Room X

Chair: L. Bubendorf, CH; M. Tsao, CA

11:00 - 11:20 Small biopsy and cytology diagnosis

, UKA. Nicholson

11:20 - 11:40 Adenocarcinoma: What are the issues?

, NY/USW. Travis

11:40 - 12:00 Tumours with squamous differentiation: What are the issues?

, CAM. Tsao

12:00 - 12:20 Undifferentiated tumours: What are the issues?

, UKK. Kerr


11:00 - 12:30 Approach to sulcus superior tumours Room C

Chair: E. Vallières, US; D. Grunenwald, FR

11:00 - 11:05 Introduction

, USE. Vallières

11:05 - 11:20 Superior sulcus tumours: the case for multidisciplinary approach

, FRD. Grunenwald

11:20 - 11:35 Transmanubrial approach

, JPH. Asamura

11:35 - 11:50 Vertebral resection

, DEJ. Schirren

11:50 - 12:05 The role of systemic therapy

, NLE. Smit

12:05 - 12:20 The role of radiotherapy

, BEP. Van Houtte




11:00 - 12:30 Are there new targets in advanced NSCLC? Room B

Chair: Y.-L. Wu, CN; D. Gandara, US

11:00 - 11:20 Update of the French oncogenic platform

, FRF. Barlesi

11:20 - 11:40 Squamous carcinoma and its own targets

, DER. Thomas

11:40 - 12:00 Lung cancer master protocols in the US

, USD. Gandara

12:00 - 12:20 New targets relevant after the era of EGFR and ALK

, ESE. Felip


11:00 - 12:30 Locally-advanced NSCLC: Addressing the challenges of large-volume disease Room A

Chair: C. Le Pechoux, FR; R. Dziadziuszko, PL

11:00 - 11:20 Large volume LA-NSCLC disease: Definition and outcomes

, NLM. Dahele

11:20 - 11:40 Is concurrent CT-RT superior in all large volume tumours?

, BED. De Ruysscher

11:40 - 12:00 Use of IMRT and proton therapy: Experimental or ready for prime-time?

, DEM. Stuschke

12:00 - 12:20 How to incorporate new agents and immunotherapy into the stage III treatment paradigm?

, PLR. Dziadziuszko




12:30 - 12:30 TUMOUR BIOLOGY AND PATHOLOGY

12:30 - 12:30 2P - EGFR mutation is not a rare issue for peripheral squamous carcinoma of lung

, L. Zhu, P. Gu, Y. Zhang, B. Han, J. Zhang; CNQ. Zhang

12:30 - 12:30 3P - EGFR mutations in non-small cell lung cancer in South Africa

, C. Maske, P. Ruff; ZAS.W. Chan



12:30 - 12:30 5P - Reliable EGFR mutation testing in ultrasound guided supraclavicular lymph node fine needleaspirates: A cohort study with diagnostic performance analysis

, S. Tiwari, V. Sovani, D. Baldwin, M. Kumaran; UKA. Awwad

12:30 - 12:30 6P - Screening for the prevalence of EGFR and ALK mutations in lung adenocarcinoma patients inthe Levant area, a prospective analysis

, M. Khalil , A. Mina , H. Rafei , N. Fakhreddin , R. Mahfouz , F. Farhat , S. Hamouri , H.A. Tfayli1 2 1 1 1 1 1 3

Dbouk , G. Zaatari ; LB, US, JO1 1 1 2 3

12:30 - 12:30 7P - Frequency of ALK gene rearrangement in Saudi lung cancer

, H. Al Husaini, S. Mohammed, A. Tulbah, K. Al Kuraya; SAF. Al Dayel

12:30 - 12:30 8P - PD1/PD-L1 expression in NSCLC differs according to localisation, grading and subtype

, A. Csanadi, C. Kayser, S. Wiesemann, J. Rawluk, M. Werner, G. Kayser; DEF. Brühl

12:30 - 12:30 9P - Distribution of T cells in non-small cell lung cancer tissue according to COPD and smokingstatus

, M. Zemaitis, D. Pranys, B. Sitkauskiene, S. Miliauskas, R. Sakalauskas; LTJ. Jackute

12:30 - 12:30 10P - Allele frequency of ABO and Rh blood group and the risk of non small cell lung carcinoma

, N. Kumar, A. Kalwar, S. Narayan, R. Nirban, S. Jakhar, S. Beniwal, N. Sharma, H. Kumar, A.A. KapoorSharma; IN

12:30 - 12:30 11P - The comparative estimation of estrogen receptor beta expression in primary and metastaticlung cancer

, E. Dudko, E. Bogush, A. Grishanina, V. Kirsanov, R. Ramanauskaite, B. Polotsky, S.T. BogushTjulandin, M. Davydov; RU

12:30 - 12:30 12P - A molecular case–control investigation of the merkel cell polyomavirus prevalence inVietnamese non-small-cell lung-cancer

, VNT. Ngo

12:30 - 12:30 13P - Expression of IRAK-1 and EZH-2 in imprints of NSCLC and preneoplastic lesions

, A.-M. Athanassiadou, E. Haini, A. Tsipis, M. Gonidi, P. Athanassiadou; GRK. Hainis

12:30 - 12:30 14P - “Different trend” in multiple primary lung cancer and intrapulmonary metastasis

, G. Che; CNC. Shen

12:30 - 12:30 15P - Clinicopathological analysis of primary pulmonary lymphoepithelioma-like carcinoma

, G. Che; CNC. Shen

12:30 - 12:30 16P - Comprehensive analysis of driver mutations in Chinese squamous cell lung carcinomas bytargeted next-generation sequencing

, D. Tao, S. Yang, X. Han, D. Wu, N. Zhang; CNY. Shi

12:30 - 12:30 17P - Identifying the genetic landscape of squamous cell carcinoma (SCC) and adenosquamouscarcinoma (ASC) of the lung using next-generation sequencing (NGS)

, L. Balabanski, D. Toncheva, G. Kurteva, D. Damyanov, P. Chilingirov; BGN. Chilingirova

12:30 - 12:30 18P - Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as serum marker of bonemetastases from non-small cell lung cancer (NSCLC) and breast cancer. Preliminary results

, A. Del Conte, F. Mazza, S. Basso, G. Chiara; ITF. Lumachi



12:30 - 12:30 19P - Fine needle aspiration cytology of thymic epithelial neoplasms: A cytologic-histologiccorrelation analysis from a referral institution

, PHF.J. Templo

12:30 - 12:30 PREVENTION, EARLY DETECTION, EPIDEMIOLOGY, TOBACCO CONTROL

12:30 - 12:30 25P - A common BIM deletion polymorphism was associated with the risk of lung cancer in aChinese population

, CNX. Jing

12:30 - 12:30 27P - Characteristics of lung cancer diagnosed with low dose chest CT screening

, C. Lee; KRS. Choi

12:30 - 12:30 28P - Sex differences in presentation, management and prognosis of Moroccan patients with nonsmall cell lung carcinoma: A retrospective analysis of 224 cases


12:30 - 12:30 29P - The risk of lung cancer among women who start smoking as teenagers

, NGM. Tagbarha

12:30 - 12:30 30P - The beliefs, orientation, knowledge, understanding, attitudes and treatment access to lungcancer amongst rural men in Nigeria

, NGM. Tagbarha

12:30 - 12:30 31P - Plasma CRABP2 in patients with non-small cell lung cancer

, H.-Y. Lee, S.-J. Lee, W.J. Kim, Y. Hong, E.J. Lee; KRS.-S. Han

12:30 - 12:30 32P - Epidemiology, treatment patterns and survival outcome in patients of advanced stageinoperable lung cancer: A tertiary cancer care centre analysis

, M. Pant, S. Singh; IND. Kumar

12:30 - 12:30 33P - Idiopathic pulmonary fibrosis as a poor prognostic factor in lung cancer patients

, S. Um, M.-S. Roh; KRC. Son

12:30 - 12:30 TRANSLATIONAL RESEARCH

12:30 - 12:30 41P - The comparative estimation of TUBB3 expression in non-small-cell lung carcinoma andadjacent lung tissue

, I. Mamichev, E. Dudko, A. Grishanina, R. Ramanauskaite, N. Vichljantzeva, S. Tjulandin, B.T. BogushPolotsky, M. Davydov; RU

12:30 - 12:30 42P - Biological role of prognostic microRNAs (miRNAs) in squamous lung carcinoma (SCC) cells

, M. Skrzypski, G. Stasioj, J. Bigda; PLM. Filipska

12:30 - 12:30 43P - miR31-3p expression in patients with advanced lepidic adenocarcinoma (L-ADC) treatedwith EGFR TKI in IFCT 0401 and 0504 trials

, M. Wislez, C. Vazart, V. Decaulne, J. Mazieres, S. Friard, P. Merle, F. Morin, F. Liebaert, J.R. ThiebautCadranel; FR

12:30 - 12:30 44P - Upregulated miRNA 21 in KRAS mutated patients is related to prognosis in resectablenon-small cell lung cancer



, S. Calabuig-Fariñas, E. Jantus-Lewintre, D. Montaner, E. Escorihuela, A. Blasco, R. Guijarro,S. GallachC. Camps; ES

12:30 - 12:30 45P - MicroRNA expression profiling in lung cancer and normal tissue using massively parallelsequencing technique

, S.-Y. Song, K.-H. Lim, S.-J. Lee, S.-S. Han, W.J. Kim; KRH.-Y. Lee

12:30 - 12:30 46P - Antitumor efficacy of the double suicide genes in lung cancer cells

, G. Che; CNC. Shen

12:30 - 12:30 47P - Pharmacogenetics & treatment outcome in cancer patients receiving radio-chemotherapy

, V. Chauhan, D. Parmar; INS. Yadav

12:30 - 12:30 48P - Development of resistance models to tyrosine kinase inhibitors (TKIs) in patient-derivedxenograft models (PDXs) of lung adenocarcinoma with epidermal growth factor receptor (EGFR)mutations

, S. Sakashita , T. Wang , N.-A. Pham , M. Li , G. Liu , M. Tsao ; ON/CA, CAE. Stewart1 1 1 1 1 1 2 1 2

12:30 - 12:30 49P - Synergistic effect of histone deacetylase inhibitor in combination with epidermal growthfactor receptor tyrosine kinase inhibitor in EGFR-TKI resistant non-small cell lung cancer celllines

, N. Zhang, J. Yao, Y. Shi; CNX. Han

12:30 - 12:30 50P - Enumeration and molecular characterization of circulating tumor cells in lung cancerpatients using the GILUPI CellCollector, an effective in vivo device for capturing CTCs

, T. Gorges, N. Penkalla, B. Nowack, T. Schalk, S. Riethdorf, K. Lücke, K. Pantel, T.N. ScheumannKrahn, C. Schumann; DE

12:30 - 12:30 51P - Gef gene: A new suicide gene therapy for non-small cell lung cancer

, R. Hernández, G. Perazzoli, J. Oliver, L. Cabeza, C. Jiménez-Luna, M. Leiva, J.A. Rama BallesterosJiménez, J. Prados; ES

12:30 - 12:30 52P - Multiparameter ploidy profiling: A powerful tool to investigate the genomics of diploid tumorpopulations

, S. Rau , V. Perrina , M. Barrett , C. Ruiz , L. Bubendorf ; CH, AZ/UST. Lorber1 1 1 2 1 1 1 2

12:30 - 12:30 IMAGING AND STAGING

12:30 - 12:30 55P - Proposed new simple criteria of clinical multiple primary lung cancers

, K. Suzuki, K. Takamochi, S. Oh; JPT. Matsunaga

12:30 - 12:30 56P - FDG PET/CT for evaluation of mediastinal lymph node staging using FDG uptake andvolumetric CT histogram in non-small cell lung cancer

, S.M. Lee, J.-H. Lee; KRJ.W. Lee

12:30 - 12:30 SCLC

12:30 - 12:30 57P - Inhibition of the focal adhesion kinase has anti-tumoral effect in small-cell lung cancer celllines

, M. Lecocq , B. Detry , L. Maha , P.P. Massion , Y. Sibille , C. Pilette , S. Ocak ; BE, F. Aboubakar1 1 1 1 2 1 1 1 1

TN/US2



12:30 - 12:30 58P - Radiation therapy (RT) in the palliative treatment of metastatic small cell lung cancer (SCLC)

, I. Ivanova, I. Gulidov, Y. Mardynsky, A. Zolotkov, D. Gogolin, L. Kursova; RUY. Ragulin

12:30 - 12:30 EARLY STAGE NSCLC

12:30 - 12:30 66P - Prognostic classification of lung adenocarcinoma by integrated miRNA-mRNA expressionprofiles

, M. Pintilie , N. Liu , J. McPherson , M. Tsao ; ON/CA, CAS. Tam1 1 1 2 2 1 2

12:30 - 12:30 67P - mRNA expression level of lymphangiogenesis-associated genes in early-stage non-smallcel lung cancer

, M. Kozlowski, W. Laudanski, J. Kisluk, J. Niklinski; PLO. Kowalczuk

12:30 - 12:30 68P - The utility of actinin-4 protein overexpression as a predictive biomarker for therapeuticeffect of adjuvant chemotherapy to the resected lung adenocarcinoma

, Y. Fujiwara , T. Kakuya , K. Tsuta , S. Watanabe , W. Huang , T. Yamada , H. AsamuraH. Shiraishi1 1 1 1 1 2 1

, Y. Ohe , K. Honda ; JP, TW1 1 1 1 2

12:30 - 12:30 69P - The impact of genetic alteration on recurrence in patients with resected stage I non-smallcell lung cancer

, E.Y. Heo, S.S. Park, Y.S. Park, Y.W. Kim, D.K. Kim; KRH.S. Chung

12:30 - 12:30 70P - Prognostic role of T-regulatory cells in completely resected early stage non-small cell lungcarcinoma

, H. Abali , A. Fndkcoglu , T. Canpolat , A. Besen , A. Sumbul , H. Mertsoylu , A. Sedef , O.F. Kose1 1 1 1 1 1 2 1

Ozyilkan ; TR, TN1 1 2

12:30 - 12:30 71P - Outcome after SBRT for potentially operable NSCLC patients

, H. Peulen, H. van Tinteren, M. Wouters, J.-J. Sonke, P. Baas, E. Smit, J. Belderbos; NLM. Rossi

12:30 - 12:30 72P - Occurrence of significant tumor volume changes during stereotactic body radiation therapyfor lung cancer

, L. Moretti, Y. Jourani, T. de Brouwer, P. Van Houtte; BEF. Charlier

12:30 - 12:30 73P - Outcome of early-stage lung cancer treated with stereotactic body radiotherapy (SBRT)

, J. Chan, A. Pope, A. Haridass, A. Baker, S. Meara, R. Clements, A. Crabtree, H. Wong,M. AlameddineC. Eswar; UK

12:30 - 12:30 74P - Does a higher surgical resection rate in lung cancer lead to a higher rate of post-operativemulti-station N2 disease?


12:30 - 12:30 75P - Adequacy of lymph node sampling during surgical resection of lung cancer at a regional UKthoracic surgical centre 2011-2013

, S. Britton, H. Al-Najjar, P. Crosbie, M. Jones, P. Bishop, P. Krysiak, K. Rammohan, R. Shah,M. EvisonR. Booton; UK

12:30 - 12:30 76P - Result of the 6-minute walk test is an independent prognostic factor of surgically treatednon-small cell lung cancer

, M. Badocha, D. Wnuk, A. Mosiewicz, W. Rzyman; PLT. Marjanski



12:30 - 12:30 77P - Post-operative outcomes in non-small cell lung cancer patients with mild to moderate stagechronic obstructive pulmonary disease

, S. Marumo, S. Kumagai, K. Yamanashi, J. Tokuno, R. Sumitomo, T. Shoji, C. Huang, M. Fukui;R. ItotaniJP

12:30 - 12:30 78P - Examination of prognostic factors in cases receiving UFT as postoperative adjuvantchemotherapy for lung cancer

, R. Yoneyama, M. Kakihana, N. Kajiwara, T. Ohira, N. Ikeda; JPK. Nawa

12:30 - 12:30 79P - Volume changes with hypo-fractionated radiotherapy in early lung cancer: Time trends &outcomes

, A. Tibdewal, S. Ghosh Laskar, S. Chaudhari, J.P. Agarwal; INR. Pathak

12:30 - 12:30 80P - Role of treatment in international differences in one-year mortality from early stagenon-small cell lung cancer: A tentative answer from the International Cancer BenchmarkingPartnership study

, M. Peake , J. Butler , M. Coleman , W. Evans , E. Jakobsen , M. Boyer , T. JohannesenT. Solomon1 1 1 1 2 3 4

, B. Rachet ; UK, ON/CA, DK, NSW/AU, NO5 1 1 2 3 4 5

12:30 - 12:30 LOCALLY ADVANCED NSCLC

12:30 - 12:30 84P - Trimodality therapy including radical resection for pancoast tumors: T4 is not acontraindication for radical surgery

, R. Waseda, T. Klikovits, O. Foesleitner, S. Zoechbauer-Mueller, K. Dieckmann, H. Prosch, R.M. HodaPirker, W. Klepetko; AT

12:30 - 12:30 85P - Review of radical radiotherapy +/- chemotherapy for stage III NSCLC

, R. Evans, E. Rees, C. Bullock; UKM. Button

12:30 - 12:30 86P - Can concurrent chemo-radiation be delayed by induction chemotherapy in the curativetreatment of stage III non-small cell lung carcinoma?: A pooled analysis

, A. Garant , M. Almajed , S. Faria , S. Owen , M. Duclos , L. Ofiara , J. Gruber , V.C. Guilbault1 2 1 1 1 1 1 1

Hirsh , N. Kopek ; QC/CA, CA1 1 1 2

12:30 - 12:30 87P - What to do for the treatment of non small cell lung cancer (NSCLC) with a single mediastinallymph node involvement (N2a disease) in developing countries?

, H. Hafizi, A. Mezini, D. Xhemalaj, I. Skenduli; ALF. Caushi

12:30 - 12:30 88P - Omission of elective nodal irradiation has no impact on isolated elective nodal failure andsurvival outcomes in stage III non-small-cell lung cancer patients treated with definitiveconcurrent chemoradiotherapy


12:30 - 12:30 89P - Clinical factors of nodal upstaging in pathologic N1 or N2 non-small cell lung cancer

, S.W. Sung, K.S. Kim, J.K. Park; KRY. Moon

12:30 - 12:30 90P - Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin in inoperable stageIII non-small cell lung cancer

, F. Kose , A. Sedef , O. Dogan , C. Parlak , A. Besen , A. Sumbul , A. Sezer , A.H. Mertsoylu1 2 2 2 2 2 2 2

Fndkcoglu , S. Muallaoglu ; TN, TR2 2 1 2



12:30 - 12:30 91P - Definitive concomitant radiochemotherapy (RCT) treatment for locally advanced (LA) nonsmall cell lung cancer (NSCLC): Evaluation of hematological and esophageal toxicity in theRadiation Oncology Department of University of Florence experience

, D. Scartoni, I.F. Furfaro, G. Simontacchi, C. De Luca Cardillo, B. Agresti, C. Talamonti, L. Livi;V. ScottiIT

12:30 - 12:30 92P - Social deprivation and radical treatment of stage III NSCLC

, R. Evans, C. Bullock, E. Rees; UKM. Button

12:30 - 12:30 93P - The clinical characteristics of 50 patients with radiation-induced pneumonia

, Q. Zhang, X. Wang; CNR. Liu

12:30 - 12:30 94P - Lung cancer in women, a different disease: Survival differences by sex

, S.T. Tokluoglu, M. Kös, K. Silay, S. Akinci, B. Oksuzoglu, N. Alkis; TRA. Ulas

12:30 - 12:30 ADVANCED NSCLC

12:30 - 12:30 111P - Ceritinib treatment of patients (Pts) with ALK-rearranged (ALK+) non-small cell lung cancer(NSCLC) and brain metastases: ASCEND-1 trial experience

, R. Mehra , D. Tan , E. Felip , T. Szczudlo , S. Sutradhar , K. Rodriguez Lorenc , A. ShawD.-W. Kim1 2 3 4 5 5 5

; KR, PA/US, SG, ES, NJ/US, US6 1 2 3 4 5 6

12:30 - 12:30 112P - Efficacy and safety of imprime PGG, a novel innate immune modulator, in combination withbevacizumab (Bev), carboplatin and paclitaxel for the 1st-line treatment of stage IV NSCLC

, W. Engel-Riedel , F. Schneller , M. Wolf , W. Schuette , J. Lowe , P. Mattson , M. GarganoA. Braun1 2 2 2 2 1 1

, M. Patchen , R. Huhn ; US, DE1 1 1 1 2

12:30 - 12:30 113P - Anlotinib as third-line treatment in patients with refractory advanced non-small cell lungcancer: A multicentre, randomized, double-blind, placebo-controlled, phase II trial (NCT01924195)

, K. Li, Y. Zhao, B. Li, Y. Cheng, J. Zhou, Y. Lu, Y. Shi, Z. Wang, L. Jiang; CNB. Han

12:30 - 12:30 114P - A phase 1b study of anti-DLL4 (delta-like ligand 4) antibody demcizumab (DEM) withpemetrexed (PEM) and carboplatin (CARBO) in patients with 1st-line non-squamous NSCLC

, M. McKeage , D. Kotasek , B. Markman , M. Hidalgo , M. Millward , M. Jameson , D.J. Dupont1 2 3 3 4 5 2

Harris , R. Stagg , B. Hughes ; CA/US, NZ, AU, ES, WA/AU, US, QLD/AU2 6 7 1 2 3 4 5 6 7

12:30 - 12:30 115P - KIF5B & CCDC6 RET in lung cancer: Clinical insights and response to personalized basedtherapy

, A. Moore, M. Gottfried, R. Katznelson, H. Nechushtan, M. Wolner, V. Neiman, L.M. SarfatySoussan-Gutman, A. Dvir, N. Peled; IL

12:30 - 12:30 116P - Clinical characteristics and response to EGFR TKI in never smoker squamous lung cancer

, S. Young, E.H. Tan, D. Lim, G.S. Tan, A. Jain, W. Zeng, T. Lim, A. Takano, D. Tan; SGS. Ee

12:30 - 12:30 117P - German country-wide surveys from 2012 and 2014 about EGFR mutational testingalgorithms adopted by medical doctors in patients with NSCLC

, D. Ukena, S. Radke, A. Freitag, S. Hörnig; DEH. Ostermann

12:30 - 12:30 118P - Erlotinib as first-line treatment for patients with advanced EGFR mutation-positivenon-small-cell lung cancer: Phase IIIB study

, B. Perin, M. Cekic, M. Rancic, V. Kovcin, Z. Andric, Z. Murtezani, D. Jovanovic, M. Velinovic, M.B. ZaricMarkovic; RS



12:30 - 12:30 119P - Reversible versus irreversible EGFR tyrosine-kinase inhibitors for non-small-cell lungcancer (NSCLC): A preclinical and pharmacokinetic comparison

, T. Friess , D. Shames , M. Wright , C. Hop ; CA/US, DEB. Liederer1 2 1 1 1 1 2

12:30 - 12:30 120P - Is switch maintenance therapy mandatory for EGFR mutated patients initiated onchemotherapy?

, INR. Roy

12:30 - 12:30 121P - Serum carcinoembryonic antigen levels predicts the efficacy of EGFR-TKI in non-small celllung cancer harboring EGFR mutations

, B. Han, B. Jin, Y. Lou, R. Li, X. Zhang, S. Hu; CNY. Zhang

12:30 - 12:30 122P - Icotinib as first-line treatment for elderly patients with EGFR 19 or 21 mutation in advancedNSCLC: A phase-IV, open-label, single-arm study

, C. Shi, J. Qian, R. Li; CNB. Han

12:30 - 12:30 123P - Outcomes of octogenarian (80 yo) patients with advanced non-small cell lung cancer(NSCLC): A single institution experience from The Christie Hospital

, J. Chiramel, N. Flaum, A. Lewis, Y. Summers, P. Taylor, A. Chittalia, H. Sheikh, F. Blackhall,M. HowellR. Califano; UK

12:30 - 12:30 124P - Platinum based chemotherapy for the treatment of elderly patients with metastatic nonsmall cell lung carcinoma: A retrospective analysis of a single institution


12:30 - 12:30 125P - A prospective randomized phase III study of palliative chemotherapy versus bestsupportive care in elderly patients with advanced non-small cell lung cancer: Survival analysisand ECOG performance status regression analysis

, A. Kapoor, A. Kalwar, S. Narayan, M. Singhal, A. Kumar, S. Lal, R. Nirban, M.N. KumarParamanandhan, R. Purohit; IN

12:30 - 12:30 126P - Outcomes over a decade in stage IV non-small cell lung cancer (NSCLC): The ClatterbridgeCancer Centre experience

, H. Wong, E. Marshall; UKC. Escriu

12:30 - 12:30 127P - A prospective randomized phase III study evaluating quality of life in advanced non-smallcell lung cancer receiving platinum based chemotherapy combination in old versus new standardchemotherapy regimen

, A. Kapoor, S. Dutta; INA. Rungta

12:30 - 12:30 128P - Comparison of efficacy of pemetrexed plus platinum and non-pemetrexed plus platinum as1st line chemotherapy in EGFR wild type non-squamous NSCLC

, S.Y. Lee, J.S. Kim; KRE.J. Kang

12:30 - 12:30 129P - Effectiveness of first-line pemetrexed plus platinum for advanced nonsquamous non-smallcell lung cancer

, M. Luis, N. Amaral, M. Cassiano Neves, C. Camacho, A. Rodrigues, I. Pousa, J. Oliveira, I.M. BrandãoAzevedo, M. Soares; PT

12:30 - 12:30 130P - Maintenance pemeterexed in NSCLC - outcome analysis from a tertiary care center

, K. Prabhash, V. Noronha, A. Joshi; INA. Pandey

12:30 - 12:30 131P - Duration and tolerance of maintenance pemetrexed (mPem) treatment for advancednon-small cell lung cancer



, E. Josephides, E. Karapanagiotou, A. Montes, J. Spicer, R. Lal; UKP. Charlton

12:30 - 12:30 132P - Weekly carboplatin and paclitaxel in advanced non-small cell lung cancer: Good responserate but poor overall survival in a "real world" population

, V. Volk , U. Mey , P. Brossart , R. Von Moos , R. Cathomas ; CH, DEM. Mark1 2 1 2 1 1 1 2

12:30 - 12:30 133P - An estimation of the population-based survival benefit of first-line chemotherapy for lungcancer

, W. Ng, S. Jacob, G. Delaney, M. Barton; AUV. Do

12:30 - 12:30 134P - Effect of haematological adverse effects occuring during chemotherapy on response totreatment and progression free survival in advanced NSCLC

, E. Fouad, K. Nasr, H. El-Ghazaly, A. Adel; EGA. Nagy

12:30 - 12:30 135P - Significance of thyroid transcription factor 1 expression in patients with nonsquamousNSCLC treated with pemetrexed based chemotherapy

, A. Velastegui Ordoñez, R. Martínez Cabañes, A. Rosero, L. Ruiz-Giménez, J.C. Cámara, S.X. MielgoHernando, A. Hurtado, C. Olier, C. Jara; ES

12:30 - 12:30 136P - TTF1 expression in advanced non-small cell lung cancer: Impact on survival outcome

, T. Al-fayea , W. Abozeed , A. Alzahrani , M. Farooq , W. Darwish , A. Almadani , E.S. Elsamany1 2 1 2 2 2 2

Bukhari ; EG, SA2 1 2

12:30 - 12:30 137P - Risk factors for skeletal-related events in patients with non-small cell lung cancer patientswith bone metastases

, A. Bilici, S.T. Tokluoglu, S. Akinci, K. Silay, F. Paksoy Turkoz, A. Durnali, B. Oksuzoglu, N. Alkis;A. UlasTR

12:30 - 12:30 METASTASES TO AND FROM THE LUNG

12:30 - 12:30 146P - Stereotactic ablative radiotherapy (SART) of lung lesion in oligometastatic patients: Theimportance of high doses delivery

, I.F. Furfaro, D. Scartoni, L. Paoletti, M. Loi, S. Russo, S. Pallotta, B. Agresti, P. Bastiani, L. Livi;V. ScottiIT

12:30 - 12:30 147P - Different metastatic pattern according to the EGFR mutational status in a cohort of lungadenocarcinomas (ADCs): A single-institution report

, T. Franchina, A. Picone, G. Ferraro, M. Picciotto, M. Zanghì, V. Franchina, V. Adamo; ITA. Russo

12:30 - 12:30 148P - Incidence of brain metastases identified upon initial diagnosis in different histologicaltypes of lung cancer: A single department experience

, F. Popovic, I. Markelic, S. Kukulj; HRG. Drpa

12:30 - 12:30 149P - Presentation and patterns of care of lung cancer patients with brain metastasis at a tertiarycare centre In India

, R. Pathak, S. Ghosh Laskar, K. Prabhash, G. Karimundackal, J.P. Agarwal; INA. Tibdewal

12:30 - 12:30 150P - Usefulness of lung palpation through thoracotomy for metastasectomy in patients withnon-imaged pulmonary nodules


12:30 - 12:30 151P - Post-treatment effects of lung cancer on spinal fracture

, NGM. Tagbarha



12:30 - 12:30 152P - Transarterial chemoembolisation using drug-eluting microspheres DEM-TACE in lungcarcinoma metastases to the liver in humans

, K. Pyra, T. Jargieo, M. Szczerbo Trojanowska, P. Chabros, J. Milanowski; PLB. Rybacka-Chabros

12:30 - 12:30 153P - Factors affecting survival in patients with pulmonary metastases from colorectal cancerwith previously resected liver metastases who underwent lung metastasectomy


12:30 - 12:30 154P - Surgical treatment of synchronous lung metastasis in patient with osteosarcomas and softtissue sarcomas

, Y. Ragulin, A. Starodubtcev, A. Kurilchik, V. Usachev, A. Zubarev, V. Ivanov; RUE. Smolenov

12:30 - 12:30 MESOTHELIOMA

12:30 - 12:30 157P - Pleural malignant mesotheliomas over-express PD-L1

, J. Xiu , S. Millis , Z. Gatalica ; CH, AZ/US, USA. Voss1 2 2 3 1 2 3

12:30 - 12:30 158P - New therapeutic approach for mesothelioma

, M. Takahashi, Y. Ino, T. Todo, N. Ikeda; JPY. Sakata

12:30 - 12:30 159P - Impact of maintenance pemetrexed in the management of non-progressing malignantmesotheliomas after standard fist-line chemotherapy: A single institution experience

, A. Russo, A. Picone, G. Ricciardi, F. Raiti, A. Scimone, G. Chiofalo, G. Toscano, V.T. FranchinaAdamo; IT

12:30 - 12:30 160P - Pretreatment serum albumin level is an independent prognostic biomarker in malignantpleural mesothelioma

, P. Stockhammer , Y. Dong , M. Jakopovic , L. Brcic , B. Dome , B. Hegedus , M.T. Klikovits1 1 1 2 2 1 1

Samarzija , W. Klepetko , M. Hoda ; AT, HR2 1 1 1 2

12:30 - 12:30 161P - Long-term survival in adults suffered from malignant mesothelioma and pulmonarytuberculosis combined - observational study

, A. Oszywa-Chabros, J. Milanowski; PLB. Rybacka-Chabros

12:30 - 12:30 162P - Statin use and survival in malignant pleural mesothelioma (MPM)

, A. Navarro, A. Martinez, P. Martinez, C. Ortiz, L. Fariñas, E. Felip; ESS. Cedres

12:30 - 12:30 163P - Solitary fibrous tumors of the pleura: Surgical treatment, analysis of our cases fromSeptember 1999 to August 2014


12:30 - 12:30 MISCELLANEOUS

12:30 - 12:30 164P - Quality in lung cancer care: The Victorian Lung Cancer Registry pilot initial report

, S. Evans, M. Senthuren, P. McLaughlin, J. McNeil; VIC/AUR. Stirling

12:30 - 12:30 165P - Preoperative positron emission tomography fractal biopsy of thymic epithelial neoplasm

, G. Felloni, M. Salgarello, A. Viti, A. Bianchi, A. Terzi; ITL. Bertolaccini



12:30 - 12:30 166P - Accuracy of pleural carcinoembryonic antigen (CEA) assay in patients with benign andmalignant pleural effusions requiring thoracentesis


12:30 - 12:30 167P - Improved quality of life of patients with malignant pleural effusion who underwentvideo-assisted minimally invasive thoracentesis and talc pleurodesis


12:30 - 12:30 168P - Malignant pleural effusion biomarkers as predictor for chemical pleurodesis success

, EGS. Alsayed

12:30 - 12:30 169P - Incidence of pain among lung cancer patients hospitalized in Palliative Care Department ofComprehensive Cancer Center – Vratsa for the period 2009 – 2013

, S. Aleksandrova, D. Yordanova; BGN. Yordanov

12:30 - 12:30 170P - Anterior mediastinal mass case series

, P. Shivanna, S. Kumar, D. Pandey, S.V.S. Deo, N.K. Shukla; INP. Ramanathan

12:30 - 12:30 171P - Surgical treatment of mediastinal neurogenic tumors and dumbell syndrome in adults: A12-year experience, January 2002 to January 2014


12:30 - 12:30 172P - Post-surgical follow-up for non-small cell lung carcinoma (NSCLC): Challenging currentpractice

, M. Haris, I. Hussain, S. Ghosh; UKF. Iqbal

12:30 - 12:30 173P - Misdiagnosis of lung tuberculosis leads to delaying in lung cancer diagnosis andtreatment: Time to use anti-tuberculosis treatment judiciously

, INR. Devgan

12:30 - 12:30 174P - Mesenchymal tumors of the mediastinum and the role of surgery in their treatment

, H. Hafizi, A. Mezini, I. Skenduli, D. Xhemalaj; ALF. Caushi

12:30 - 12:30 175P - A novel technique for the management of reccurent malignant pericardial effusions

, D. Patrini, B. Adams, D. Lawrence; UKN. Panagiotopoulos

12:30 - 12:30 176P - Feasiblity of endoscopic transumbilical anatomic lobectomy in a canine model

, TWY.-H. Liu

12:30 - 12:30 TRIALS IN PROGRESS

12:30 - 12:30 95TiP - A phase 3, randomised, double-blind, placebo-controlled, International study of MEDI4736in patients with locally advanced, unresectable, stage 3 NSCLC who have not progressedfollowing platinum-based, concurrent chemoradiation therapy (PACIFIC)

, N. Iannotti , M. Salamat , D. Jayawardene , M. Ballas , P. Stockman , S. Antonia ; B. Creelan1 1 2 3 3 4 1 1

FL/US, KS/US, MD/US, UK2 3 4

12:30 - 12:30 138TiP - Ceritinib in patients (pts) with anaplastic lymphoma kinase (ALK)-rearranged (ALK+)non-small cell lung cancer (NSCLC) metastatic to the brain and/or leptomeninges: The phase IIASCEND-7 study

, F. Barlesi , E. Bertino , D.-W. Kim , M. van den Bent , H. Wakelee , P. Wen , P. CazorlaL. Chow1 2 3 4 5 6 7

Arratia , J. Shen , F. Branle ; US, FR, OH/US, KR, NL, CA/US, MA/US, NJ/US, CH8 8 9 1 2 3 4 5 6 7 8 9



12:30 - 12:30 139TiP - Phase 2, open-label, international, non-comparative study of MEDI4736 in patients withlocally advanced or metastatic, PD-L1+, stage 3B–4 NSCLC who have received 2 prior systemictreatment regimens (ATLANTIC)

, M. Garassino , J. Vansteenkiste , M. Ballas , D. Jayawardene , P. Stockman , J. Powderly ,J. Gray1 2 3 4 4 5 6

N. Rizvi ; FL/US, IT, BE, MD/US, UK, NC/US, NY/US7 1 2 3 4 5 6 7

12:30 - 12:30 140TiP - AURA3 design: a randomised, Phase III study of AZD9291 versus second-linechemotherapy for patients (pts) with EGFR-TKI-resistant (T790M) advanced non-small cell lungcancer

, V. Papadimitrakopoulou , S. Ghiorghiu , A. Templeton , T. Mok ; CN, TX/US, UKY.-L. Wu1 2 3 3 1 1 2 3

12:30 - 12:30 141TiP - AZD9291, a third generation EGFR inhibitor, versus gefitinib or erlotinib intreatment-naïve patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring anEGFR-TKI-sensitising mutation (EGFRm): A randomised, phase III study (FLAURA)

, Y. Rukazenkov , K. Thomas , J.-C. Soria ; GA/US, UK, FRS. Ramalingam1 2 2 3 1 2 3

12:30 - 12:30 142TiP - Randomized, double-blind, placebo-controlled trial of evofosfamide (TH-302) incombination with pemetrexed in advanced non-squamous non-small cell lung cancer

, C. Belani , S. Novello , J. von Pawel , T. Csoszi , S. Orlov , S. Kroll , T. Pearce ; J. Goldman1 2 3 4 5 6 1 2 1

CA/US, US, IT, DE, HU, RU2 3 4 5 6

12:30 - 12:30 143TiP - SPECTAlung: Screening patients with thoracic tumors for efficient clinical trial access

, J. Menis , J. Adam , R. Dziadziuszko , B. Hasan , L. Lacroix , S. Peters , D. Lacombe , M.B. Besse1 2 1 3 2 1 4 2

O'Brien , R. Stahel ; FR, BE, PL, CH, UK5 4 1 2 3 4 5

12:30 - 12:30 144TiP - Open-label single-arm phase IV study to assess the efficacy and safety of afatinib assecond-line therapy for patients with locally advanced or metastatic non-small cell lung cancer(NSCLC) harbouring common epidermal growth factor receptor (EGFR) mutations (Del19 and/orL858R) who have failed first-line treatment with platinum-based chemotherapy

, H. Jones , A. Cseh , R. Gaafar ; TH, UK, AT, EGS. Thongprasert1 2 3 4 1 2 3 4

14:30 - 16:00 Multidisciplinary Tumour Board: How do we approach oligoprogressive disease? Room B

Chair: U. Ricardi, IT; D. Grunenwald, FR; J. Vansteenkiste, BE

14:30 - 15:00 Controlled EGFR mutant disease and one rapidly growing lung nodule

, CNY.-L. Wu

15:00 - 15:30 Crizotinib-controlled ALK positive disease and three brain metastases

, CHM. Guckenberger

15:30 - 16:00 Cycle 28 pemetrexed maintenance therapy and one enlarging adrenal gland

, ITF. de Marinis

14:30 - 15:45 Epidemiology, early stage NSCLC and surgery Room V

Chair: G. Rocco, IT; E. Quoix, FR; J.-P. Sculier, BE

14:30 - 14:30 21PD_PR - Perception of lung cancer (LC) risk: Impact of smoking status and nicotinedependence



, S. Couraud, C. Touboul, J. Viguier, F. Eisinger, J.-F. Morère, X. Pivot, J.-Y. Blay, C. Lhomel,L. GreillierA. Cortot; FR

14:30 - 14:30 26PD - The effect of emergency presentation on surgery and survival in lung cancer patients inEngland, 2006-2008

, R. Jack, H. Møller, M. Lüchtenborg; UKD. Tataru


, FRE. Quoix


14:45 - 14:45 22PD - Body mass index and lung cancer survival: Results from the ICARE study

, G. Clain, M. Sanchez, A.V. Guizard, A.S. Woronoff, B. Tretarre, F. Molinie, P. Delafosse, D.H. SanikiniLuce, I. Stücker; FR

14:45 - 14:45 24PD - Predicting Early Lung Cancer Using Big Data

, L. Ma, L.W. Tao, M.F. Han, L.M. Ma; CNY. Ge

14:45 - 14:45 54PD - Advantages of diffusion weighted imaging of pulmonary nodules and masses:Comparison with positron emission tomography

, M. Sagawa, N. Motono, M. Ueno, M. Tanaka, Y. Machida, S. Maeda, M. Matoba, H. Tonami,K. UsudaY. Ueda; JP

14:45 - 14:45 65PD - Prognostic influence of mutational status in resected non-small cell lung cancer: TheKRAS G12V worse value

, P.-E. Falcoz, M. Schaeffer, M. Beau-Faller, B. Romain, A. Olland, J. Reeb, N. Santelmo, G.S. RenaudMassard, A.-C. Voegeli; FR


, BEJ.-P. Sculier


15:15 - 15:15 63PD - Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically orwith stereotactic radiotherapy: Results from propensity score analysis

, N.E. Verstegen, A. Maat, O. Birim, A. Bogers, M. Mokhles, F. Lagerwaard, S. Senan, J.S. MokhlesTakkenberg; NL

15:15 - 15:15 64PD - Effect of comorbidity on surgery and survival among lung cancer patients in England

, S. Riaz, R. Jack, M. Peake, M. Lind, H. Møller; UKM. Lüchtenborg

15:15 - 15:15 110PD - Single organ metastatic disease, a new prognostic factor for overall survival (OS) in stageIV non-small cell lung cancer (NSCLC)

, J. Derks, P. Postmus, R. Damhuis, R. Houben, E. Troost, M. Hochstenbag, E. Smit, A.-M.L. HendriksDingemans; NL


, ITG. Rocco




16:30 - 18:00 Expanding the role of biomarkers Room A

Chair: R. Thomas, DE; C. Zhou, CN

16:30 - 16:50 Biomarker testing beyond EGFR and ALK: Expanding the list of tests

, CNC. Zhou

16:50 - 17:10 Biomarker testing on cytology samples

, CHL. Bubendorf

17:10 - 17:30 Biomarker testing: Challenges in delivering the service

, USF. Hirsch

17:30 - 17:50 NGS techniques: Ready for ‘prime time’?

, DER. Büttner


16:30 - 18:00 ESMO-IASLC Best Abstracts Room B


16:30 - 16:45 35O_PR - Investigating the utility of circulating-free tumour-derived DNA (ctDNA) in plasma forthe detection of epidermal growth factor receptor (EGFR) mutation status in European andJapanese patients (pts) with advanced non-small-cell lung cancer (aNSCLC): ASSESS study

, K. Hagiwara , B. Han , S. Tjulandin , C. Grohe , T. Yokoi , A. Morabito , R. McCormack ,M. Reck1 2 3 4 1 2 5 6

M. Ratcliffe , N. Normanno ; DE, JP, CN, RU, IT, UK6 5 1 2 3 4 5 6

16:45 - 17:00 36O - Detection of EGFR T790M mutation in urinary circulating tumor DNA from metastaticnon-small cell lung cancer patients

, K. Kosco , S. Guerrero , T. Lu , C.R. Vibat , M. Erlander , V. Melnikova ; CA/US, USH. Husain1 1 1 1 2 1 1 1 2

17:00 - 17:15 LBA1 - Detection of circulating tumor cells and early recurrence in patients undergoing radicalresection for non-small-cell lung cancer

, M.J. Serrano, C. Giraldo, F. Ortega, F. Ruiz-Zafra, A. Sánchez-Palencia, J.C. Bayarri-LaraGarcía-Puche, M. Delgado-Rodriguez, J. Navajas, A. Cueto; ES


, NLE. Smit

17:35 - 17:50 LBA2_PR - EGFR mutation testing and oncologist treatment choice in advanced NSCLC: Globaltrends and differences

, B. Tischer , M. Peters ; UK, DE, NSW/AUJ. Spicer1 2 3 1 2 3


, CNT. Mok

04-18-2015



08:00 - 08:50 Complex non T3 –T4 and non N2 resectable disease Room X

Chair: D. Waller, UK; P. Thomas, FR

08:00 - 08:15 Pathological N1 disease: Extent of resection

, UKD. Waller

08:15 - 08:30 Invasion across the fissure: Extent of resection

, FRP. Thomas


08:00 - 08:50 Survivorship issues after stereotactic ablative RT for early-stage NSCLC Room V

Chair: G. Rocco, IT; U. Ricardi, IT

08:00 - 08:15 Predicting survival following SABR in early-stage NSCLC

, ITU. Ricardi

08:15 - 08:30 Treatment of disease detected post-SABR

, ITG. Rocco


09:00 - 10:30 Screening and early detection Room B

Chair: N. Horeweg, NL; G. Zalcman, FR

09:00 - 09:20 Chemoprevention of lung cancer

, ITA. De Censi

09:20 - 09:40 Molecular markers for early detection

, ITF. Bianchi

09:40 - 10:00 Update on European lung cancer screening randomised and non-randomised studies

, NLN. Horeweg

10:00 - 10:20 Update on CT lung cancer screening in Japan

, JPR. Kakinuma




09:00 - 10:30 Refining radiation therapy for SCLC Room A

Chair: J. Belderbos, NL

09:00 - 09:20 Radiobiology of SCLC and implications for treatment and research

, DER. Bütof

09:20 - 09:40 Up-date time-dose-fractionation-and technique for PCI in SCLC

, NLJ. Belderbos

09:40 - 10:00 Indications, efficacy and toxicity of PCI in limited and extensive disease

, FRC. Le Pechoux

10:00 - 10:20 Thoracic radiation therapy for extensive disease

, NLB. Slotman


10:30 - 11:00 ELCC Award Lecture Room B

Chair: R. Stahel, CH

11:20 - 12:50 Smoking epidemiology and smoking cessation techniques Room A

Chair: E. Quoix, FR; V. Ninane, BE

11:20 - 11:40 Molecular susceptibility for lung cancer and nicotine addiction

, FRG. Zalcman

11:40 - 12:00 Smoking cessation in screening programmes

, NY/USP. Boffetta

12:00 - 12:20 Smoking cessation in young people

, DEA. Bühler

12:20 - 12:40 Do electronic cigarettes impact on smoking cessation?

, FRE. Quoix




11:20 - 12:50 The proper treatment algorithm for non-oncogene driven NSCLC Room B

Chair: G. Scagliotti, IT; F. Hirsch, US

11:20 - 11:40 Optimal first line treatment

, GRK. Syrigos

11:40 - 12:00 Treatment of the relapsed patient

, NLA.-M. Dingemans

12:00 - 12:20 Chemotherapy for patients with brain metastases

, KRM.-J. Ahn

12:20 - 12:40 Future direction: Pharamcogenomics or new chemotherapeutic agents?

, ITG. Scagliotti


12:50 - 13:00 Closing remarks Room B


18:20 - 18:21 test Hall 1

18:20 - 18:40 test

, CHS. Fontanella


elcc 2015 final programme - · pdf filelast update: 09-03-2015 04:51:41pm elcc 2015 14:30 -...

Documents